TOBA II Clinical Study Protocol -
Tack Endovascular System
CA 0119 Rev BDCO No: 446
Effective Date: 02/10/16
CA 0119 Rev B CONFIDENTIAL Page 1 of 6Íµ 
Clinical Study Protocol 
Tack Optimized Balloon Angioplasty Study for the  
Superficial Femoral and Proximal Popliteal Arteries 
Using the Tack Endovascular Systemâ„¢ ( TOBA II ) 
Study Device: Tack Endovascular Systemâ„¢ 
Protocol Number: CA 0119 
Protocol Version: Rev B 
Effective Date: 02/10/16 
Study Sponsor: Intact Vascular, Inc.
[ADDRESS_415734] 
Wayne, Pennsylvania [ZIP_CODE] 
[LOCATION_002] of America 
This investigational protocol contains confidential information for use by [CONTACT_336512]. It should be held confidential and maintained in  a secure location. It should not be copi[INVESTIGATOR_260793]
[STUDY_ID_REMOVED]
*NCT number added post-approval per CT.gov requirement
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 2 of 6Íµ 
TABLE OF CONTENTS
Investigator Signature [CONTACT_3490].................................... ............................................................... .................................... [ADDRESS_415735] Population ....................................... ............................................................... ....................................... 23 
7.3. Anticipated Number of Subjects ........................... ............................................................... ........................ 23 
7.4. Clinical Study Duration & Follow-up ...................... ............................................................... ..................... [ADDRESS_415736] Selection ........................................ ............................................................... .......................................... 23 
7.5.1. Inclusion Criteria ..................................... ............................................................... .................................. 23 
7.5.2. Angiographic Inclusion Criteria ........................ ............................................................... ................... 24 
7.5.3. Exclusion Criteria ..................................... ............................................................... ................................. 25 
7.5.4. Angiographic Exclusion Criteria ........................ ............................................................... .................. 26 
Treatment Plan ................................................ ............................................................... .............................................. 26 
8.1. Time and Events S chedule ................................. ............................................................... .............................. 26 
8.2. Pre-Screening ............................................ ............................................................... ............................................ 28 
8.3. Obtaining Informed Consent ............................... ............................................................... ........................... 28 
8.4. Screening Success and  Failure Criteria ................... ............................................................... ................... 28 
Baseline Evaluation ........................................... ............................................................... ........................................... 29 
9.1. Baseline Assessments ..................................... ............................................................... ................................... 29 
9.2. Study medications ........................................ ............................................................... ....................................... 30 
Index Procedure ................................................ ............................................................... ............................................30
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 3 of 6Íµ 
10.1. Index Baseline Angiogram ................................ ............................................................... .......................... [ADDRESS_415737]-Angioplasty Angio graphic Requirements ............ ............................................................... . 32 
10.3. Study Device Treatment .................................. ............................................................... ............................ 33 
10.3.1. Enrollment (Intent-to-Treat) .......................... ............................................................... ...................... [ADDRESS_415738]-Dilatation of Treated  Lesion (Post-Study Device) ... .............................................................. 34 
10.4.1. Recommendations ....................................... ............................................................... .............................. 34 
10.4.2. Final Treatment Results ............................... ............................................................... ........................... 34 
10.5. Bailout Stenting of Target  Lesion (Post-Study Device) ... .............................................................. [ADDRESS_415739]-Procedure/Pre-Discharge .................................. ............................................................... ............................. 35 
11.1. Required Assessments .................................... ............................................................... ............................. 35 
Required Follow-up Visits and Assessments...................... ............................................................... ............... 35 
12.1. 30-day Follow-up Visit (-2 days / +[ADDRESS_415740]-Index Pro cedure) ....................................... 35 
12.2. 6 Month Follow-up Visit (Â± [ADDRESS_415741]-Index Procedure) . ....................................................... 35 
12.3. 12 Month Follow-up Visit ( Â±[ADDRESS_415742]-Index Procedure) ..................................................... 36 
12.4. 24 Month Follow-up Visit ( Â±[ADDRESS_415743]-Index Procedure) ..................................................... 36 
12.5. 36 Month Follow-up Visit (Â±[ADDRESS_415744]-Index Procedure) ..................................................... 36 
12.6. Review of concomitant medications (antiplatelets/anticoag ulants)Duplex Ultrasound 
(DUS) Assessment .............................................. ............................................................... ............................................... [ADDRESS_415745] Discontinuation and Replacement ................ ............................................................... .......... 38 
Risk/Benefit Assessment ....................................... ............................................................... .................................... 39 
13.1. Risks ................................................... ............................................................... .................................................. 39 
13.2. Potential Benefits ...................................... ............................................................... ..................................... 40 
13.3. Justification for Clinical Study ........................ ............................................................... ........................... 40 
Adverse Event Report ing ....................................... ............................................................... .................................... 40 
14.1. Adverse Events (AE) ..................................... ............................................................... ................................ 41 
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 4 of 6Íµ 
14.1.1. AE Reporting........................................... ............................................................... ..................................... 42 
14.2. Adverse Device Effects (ADE) ............................ ............................................................... ....................... 42 
14.2.1. ADE Reporting ......................................... ............................................................... ................................... 42 
14.3. Serious Adverse Events (SAE) ............................ ............................................................... ....................... 42 
14.3.1. SAE Reporting ......................................... ............................................................... .................................... 43 
14.4. Major Adverse Events (MAE) .............................. ............................................................... ...................... 43 
14.4.1. MAE Reporting ......................................... ............................................................... ................................... 43 
14.5. Serious Adverse Device Effects (SADE) ................... ............................................................... .............. 43 
14.5.1. SADE Reporting ........................................ ............................................................... .................................. 43 
14.6. Unanticipated Adverse Device Effects (UADE) ............. ............................................................... ..... [ADDRESS_415746] (IRB) / Ethics Committee (EC) Approval .................................... [ADDRESS_415747] ........................................ ............................................................... ........................................ 51 
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 5 of 6Íµ 
18.1. Principal Investigator  [INVESTIGATOR_336484] ........... ............................................................... ........... [ADDRESS_415748] (DSMB) ................... ............................................................... .......... 54 
18.7.2. Clinical Events Committee (CEC) ....................... ............................................................... ................. [ADDRESS_415749] Retention ....................................... ............................................................... ..................................... 55 
18.11. Audits/Inspections ..................................... ............................................................... ................................... 56 
18.12. Study Termination (Stoppi[INVESTIGATOR_1869])...................... ............................................................... ................ [ADDRESS_415750] Expenses ........................... ............................................................... ........................ 57 
18.14. Clinical Study Reports ................................. ............................................................... ................................. 57 
18.15. Publication Policies.................................... ............................................................... .................................... 58 
18.16. Medicare Study Criteria ................................ ............................................................... ............................... 58 
Study Definitions.............................................. ............................................................... .............................................59
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 6 of 6Íµ 
LIST OF ACRONYMS  
ABI Ankle Brachial Index 
ADE Adverse Device Effect 
AE Adverse Event 
CD-TLR Clinically-driven Target Lesion Revascularization 
CD-TVR Clinically-driven Tar get Vessel Revascularization 
CEC Clinical Event Committee 
CLI Critical Limb Ischemia 
CRF Case Report Form 
CTO Chronic Total Occlusion 
DCB Drug-coated Balloon 
DEB Drug Elutin g Balloon 
DES Drug Elutin g Stent 
DSMB Data Safety and Monitorin g Board 
DUS Duplex Ultrasound 
EC Ethics Committee 
eCRF Electronic CRF 
EDC Electronic Data Capture 
EQ5D EuroQol Group 5-Dimension Self-Report Questionnaire 
FDA Food and Dru g Administration 
FU Follow Up 
GCP Good Clinical Practice 
ICF Informed Consent Form 
ICH International Conference on Harmonization 
IFU Instructions For Use 
INR International Normalized Ratio 
IRB Institutional Review Board 
IVUS Intravascular Ultrasound 
LLL Late Lumen Loss 
LTFU Lost to Follow-up 
MAE Major Adverse Events 
NHLBI National Heart, Lun g, and Blood Institute 
PAD Peripheral Arterial Disease 
PAQ Peripheral Artery Questionnaire 
PI [INVESTIGATOR_336485]/platelet count 
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 7 of 6Íµ 
PPA Proximal Popliteal Artery 
PSVR Peak Systolic Velocity Ratio 
PT Prothrombin time 
PTA Percutaneous Transluminal Angioplasty 
RS Residual Stenosis 
RVD Reference Vessel Diameter 
SADE Serious Adverse Device Effect 
SAE Serious Adverse Event 
SFA Superficial Femoral Artery 
TASC Trans-Atlantic Inter-Society Consensus 
TL Target Lesion 
TLR Target Lesion Revascularization 
TV Target Vessel 
TVR Target Vessel Revascularization 
UADE Unanticipated Adverse Device Effect 
WIQ Walking Impairment Questionnaire 
% DS  Percentage Diameter Stenosis
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 8 of 6Íµ 
INVESTIGATOR SIGNATURE [CONTACT_255630]: T ACK OPTIMIZED BALLOON ANGIOPLASTY STUDY FOR THE  
SUPERFICIAL FEMORAL AND PROXIMAL POPLITEAL ARTERIES USING THE  
TACK  ENDOVASCULAR SYSTEM â„¢ (TOBA  II) 
STUDY CENTER: 
_____________________________________________ 
 (Print name [CONTACT_205425]) 
I, the undersigned, have read and understand the protocol speci fied above and agree to abide by [CONTACT_336513]. I agree to perform and conduct the study as described in the protocol. In addition, when 
applicable, I agree to enlist sub-investigators who also agree to perform and conduct the study as 
described in the protocol and I acknowledge it is my responsibi lity to ensure that is carried out. 
_______________________________________________________________ ____ 
SITE PI â€“ Print Name 
_______________________________________________________________ ____ 
SITE PI â€“ Signature 
_______________________ 
DATE 
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 9 of 6Íµ 
STUDY SYNOPSIS  
Study Title: Tack Optimized Balloon An g i o p l a s t y  S t u d y  f o r  t h e  S u p e r f i c i a l  F e m o r a l  a n d  
Proximal Popliteal Arteries Using the Tack Endovascular Systemâ„¢   (TOBA II)  
Study Design: This is a prospective, multi-center, single-arm, non-blinded st udy designed to 
investigate the safety and effica cy of the Tack Endovascular Sy stem. 
Study 
Objective: To compare the safety and efficacy of the Tack Endovascular Sys tem in subjects 
with peripheral artery disease (PAD) to a pre-defined performan ce goal (PG). 
Study Device: Tack Endovascular Systemâ„¢ manufactured by [CONTACT_336514], Inc.  
Intended Use:  The Tack Endovascular System is intended for use in the superfi cial femoral and 
proximal popliteal arteries ranging in diameter from 2.5mm to [ADDRESS_415751] percutaneous transluminal balloon angioplasty (P TA) 
dissection(s) type(s) A through F. 
Subject 
Population: Subjects with PAD who receive PTA (with a standard or FDA-appro ved Lutonix 
drug-coated balloon) in the SFA a nd proximal popliteal (P1) art eries and have a 
resulting dissection(s) type(s) A through F are eligible for en rollment. To be 
enrolled, subjects must meet all inclusion criteria and not mee t any of the 
exclusion criteria. 
Enrollment: Approximately 210 subjects will be enrolled at up to 40 clinica l sites throughout 
the U.S. and Europe (up to 5 European sites will participate) 
Primary Endpoints: Safety: Freedom from the occurrence of an y new-onset major adverse even t(s) 
(MAEs) defined as index limb amp utation (above the ankle), CEC adjudicated 
clinically-driven target lesion revascularization (CD-TLR), or all-cause death at 
30 days. 
Efficacy: Primary patency defined as freedom from CEC adjudicated clinica lly-
driven target lesion revascularization (CD-TLR) and freedom fro m core lab 
adjudicated duplex ultrasound de rived binary restenosis at 12 m onths (defined 
as PSVR >2.5). 
Observational Endpoints: D e v i c e  S u c c e s s :  S u c c e s s f u l  d e p l o y m e n t  o f  t h e  T a c k ( s )  a t  t h e  i n t ended target 
site(s) and successful withdrawal of the delivery catheter from  th e intr odu cer 
sheath. If the study device is introduced but the subject does not receive a Tack 
due to user error and not a device malfunction, this device wil l not be included in 
the device success assessment.  
Procedural Success: Demonstrated vessel patency (<30% residual DS, by [CONTACT_306060]) without the use of a bailout stent or the occurrence of MAE upon 
completion of the index procedure. 
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 10 of 6Íµ 
I n  a d d i t i o n ,  t h e  f o l l o w i n g  o b s e r v a t i o n a l  e n d p o i n t s  w i l l  b e  a s s e ssed at various 
time points through 36 months (See Section 8.1  Time and Events Schedule): 
ÂƒAll-cause death
ÂƒAmputation of the target limb (above the ankle)
ÂƒClinically-driven target vessel revascularization (CD-TVR)
ÂƒClinically-driven target lesion revascularization (CD-TLR)
ÂƒTarget vessel revascularization (TVR)
ÂƒTarget lesion revascularization (TLR)
ÂƒChanges from Baseline in R utherford Classification
ÂƒChanges from Baseline in Ankle Brachial Index (ABI) measurement
ÂƒChanges from Baseline in the Peripheral Artery Questionnaire (P AQ)
ÂƒChanges from Baseline in the EQ-5D-3L quality of life questionn aire
ÂƒChanges from Baseline in the Walking Impairment Questionnaire ( WIQ)
ÂƒTack Integrity via X-ray (only performed at 12 month visit)
ÂƒDuplex Ultrasound (DUS) derived lesion and vessel patency (perf ormed at each 
visit through 12 months)
Inclusion 
Criteria: S u b j e c t  m u s t  m e e t  a l l  o f  t h e  f o l l o w i n g  i n c l u s i o n  c r i t e r i a  t o  b e  e l i g i b l e  f o r  
enrollment:
1. Male or non-pregnant Female Î· [ADDRESS_415752] use some form of contraception  (abstinence
is acceptable) through the duration of the study
3. Target limb requires no additional treatment aside from the t arget lesion
and the iliac artery(ies) during the index procedure
4. Subject has been informed of and understands the nature of th e study and
provides signed informed consent to participate in the study. I f the subject
possesses the ability to underst and and provide informed consen t but due to
physical inability, the subject cannot sign the ICF, an imparti al witness may
sign on behalf of the subject
5. Willing to comply with all  required follow-up visits
6. Rutherford Classification 2, 3 or 47. Estimated life expectancy >[ADDRESS_415753] surgical repair, if necessary
9 . S u b j e c t  i s  a m b u l a t o r y  ( a s s i s t i v e  d e v i c e s  s u c h  a s  a  c a n e  o r  w a lker is
acceptable).
Angiographic 
Inclusion Criteria: 1. Reference vessel diameter is between 2.5 mm and 6.0 mm, inclu sive (by
[CONTACT_13729]), and able to be treated with the Study Device implant
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 11 of 6Íµ 
2. Ability to cross a guidewire (antegrade) through target lesio n
3. Has a de novo or non-stented restenotic target lesion indicat e d  f o r  P T A
treatment with a standard or FDA-approved Lutonix drug-coated b alloon
catheter that meets the following criteria below:
a . 7 0 %  t o  9 9 %  s t e n o s i s  w i t h  a  t o t a l  l e s i o n  l e n g t h  o f  Î·20mm and
Î¶Í³Í·Í²ÂÂÂ‹ÂÂÂ‡ÂÂ‰Â–ÂŠÈ‹Â„Â› Â˜Â‹Â•Â—ÂƒÂÂ‡Â•Â–Â‹ÂÂƒÂ–Â‡ÈŒÂ‘Â”Ç¢
b . 1 0 0 %  o c c l u d e d  w i t h  a  t o t a l  l e s i o n  l e n g t h  Î¶100mm (by [CONTACT_336515])
Notes:
A  t a n d e m  l e s i o n ,  d e f i n e d  a s  a  l e s i o n  c o m p r i s e d  o f  d i s e a s e d  a n d
healthy segments, is eligible if the healthy segments are each not
more than 30mm in length and all  other criteria, including 3a a nd 3b
above, are met
A combination lesion, defined as a continuous lesion with both non-
occluded and 100% occluded segments, is eligible if the lesion can be
treated as a single lesion and all other criteria, including 3a  and 3b
above, are met
c. A non-stented restenotic lesio n must meet the following crite ria:
i. Meets criter ia 3a and 3b
ii. No part of the target lesion has been previously treated wit h
a drug-coated balloon
iii. No part of the target lesion has had more than 2 previous P TA 
failures
iv. >[ADDRESS_415754] recent angioplasty treatment
4. Target lesion is in the superficial femoral artery (SFA) and/ or proximal
popliteal artery (above the knee), located Î·Í³Â…ÂÂ„Â‡ÂÂ‘Â™Â–ÂŠÂ‡Â…Â‘ÂÂÂ‘ÂÂˆÂ‡ÂÂ‘Â”ÂƒÂ
artery (CFA) bifurcation to the distal segment of the proximal popliteal (P1)
artery at the superior  end of the patella
5. Presence of at least one patent (<50% DS) infrapopliteal vess el that has not
been revascularized prior to index procedure
6. After PTA treatment, the targe t lesion has <30% residual DS and presence of
at least one post-PTA dissection (Type A-F) (by [CONTACT_13729] )
7. No evidence of aneurysm or acute thrombus in target vessel
Exclusion 
Criteria: Subject must NOT meet any of the following exclusion criteria t o be eligible for 
enrollment:
1. Rutherford Classification 0, 1, 5 or 6
2. Is pregnant or refuses to use contraception through the durat ion of the
study
3. Previous infrainguinal by[CONTACT_336516]
4. Planned amputation on the target limb
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 12 of 6Íµ 
5. Systemic infection or Infection within the target limb and/or
immunocompromised
6. Endovascular or surgical procedure (not including diagnostic procedures)
on the target limb within 30 days prior to or within 30 days af ter the index
procedure
7. Endovascular or surgical procedure (not including diagnostic procedures)
on the non-target limb within 14 days prior to the index proced ure or
planned procedure within 30 days after the index procedure
8. Prior coronary artery by[CONTACT_112906] (CABG) or percutaneous cor onary
intervention (PCI) procedure wit hin 30 days prior to the index procedure or
planned CABG/PCI within 30 day s after the index procedure
9. Any other previous or planned surgical or endovascular proced ure (not
including diagnostic procedures) within [ADDRESS_415755]
index procedure
10. Planned atherectomy, cryoplasty, stenting or any other treat ment (with the
exception of a crossing device) of the target lesion other than  PTA during
the index procedure
11. Known coagulopathy, hypercoagulable state, bleeding diathesi s, other blood
disorder, or a platelet count le ss than 80,000/microliter or gr eater than
500,000/microliter.
12. Known hypersensitivity or allergy to  antiplatelet or antico agulant therapy
13. Myocardial infarction within 30 days prior to enrollment
14. History of stroke within 90 days prior to enrollment15. Serum creatinine of >2.5 mg/dL
16. Requires treatment of tibial or outflow vessels at the index  procedure, which
include the P2 and P3 segments o f the popliteal artery and the tibioperoneal
vessels.
17. Known hypersensitivity or contraindication to nickel-titaniu m alloy (Nitinol)
18. Participating in another ongoing investigational clinical tr i a l  t h a t  h a s  n o t
completed its primary endpoint
1 9 .H a s  o t h e r  c o m o r b i d i t i e s  t h a t ,  i n  t h e  o p i n i o n  o f  t h e  i n v e s t i g ator, would
preclude them from receiving this treatment and/or participatin g in study-
required follow-up assessments
20. Known hypersensitivity or allergy to contrast agents that ca nnot be medically 
managed
21. Thrombolysis of the target vessel within 72 hours prior to t he index
procedure, where complete resolution of the thrombus was not ac hieved
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 13 of 6Íµ 
Angiographic 
Exclusion Criteria: 1. Retrograde crossing through target lesion
2. Acute vessel occlusion or acute or sub-acute thrombosis in ta rget lesion
3. Subject has significant stenosis ( Î·50% stenosis) or occlusion of ipsilateral
inflow iliac artery not successfully treated (<30% residual DS and without
complication) prior to PTA of target vessel
4. Angiographic evidence of calcification severe enough that it renders the
target lesion non-dilatable and/or has Î·Í·Â…Â  (visual estimate) of
circumferential calcification
5. The target lesion shows no dissections after PTA
6. Presence of residual diameter Â•Â–Â‡ÂÂ‘Â•Â‹Â•Î·ÍµÍ²Î¨ÂƒÂˆÂ–Â‡Â”È‹Â„ÂƒÂ•Â‡Â†Â‘ÂÂ˜Â‹Â•Â—ÂƒÂ
estimate)
7. Non-target limb requiring any vascular treatment at time of in dex
procedure
8. Previously implanted ste nt in the target vessel
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 14 of 6Íµ 
STUDY MANAGEMENT CONTACT [CONTACT_336517]: Intact Vascular. Inc. 
[ADDRESS_415756] 
Wayne, PA [ZIP_CODE] [LOCATION_003] 
Fax: [PHONE_6984] 
Marc Penna, VP of Clinical Affairs 
Mobile : [PHONE_6985] 
E-mail : [EMAIL_6529]  
Catherine Seme, Project Manager 
Mobile : [PHONE_6986] 
E-mail : [EMAIL_6530]  
Medical Monitor: Dennis Donohoe, M.D. 
Telephone: [PHONE_6987] 
Email: [EMAIL_6531]  
Medical Research 
Organization (MRO) / Data Management: NAMSA (Clinical Research Services) 
[ADDRESS_415757] 
Minneapolis, Minnesota [ZIP_CODE] 
[PHONE_6988] 
Principal Investigator (US): William A. Gray, MD 
System Chief, Division of Cardio vascular Services, Main Line He alth 
President, Lankenau Heart Instit uteLankenau MOB East Suite [ADDRESS_415758] 
Wynnewood, PA [ZIP_CODE] Telephone: [PHONE_6989] 
Email: [EMAIL_6532]  
Angiographic / X-Ray 
Core Lab, DSMB, CEC: Yale Cardiovascular Research Group 
One Church Street, Suite [ADDRESS_415759] [ZIP_CODE] Tel: [PHONE_6990] Fax: [PHONE_6991] 
Duplex UltrasoundCore Lab: VasCore 
[LOCATION_005] General Hospi[INVESTIGATOR_336486], 10
th Floor 
[LOCATION_011], MA [ZIP_CODE]  
Office: ([PHONE_6992] 
Fax: ([PHONE_6993] 
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 15 of 6Íµ 
INTRODUCTION  
4.1. B ACKGROUND AND RATIONALE  
Peripheral artery disease (PAD) is a chronic occlusive artery d isease caused by [CONTACT_336518].  Cl inical symptoms include pain 
while walking or in more severe cases rest pain or tissue loss.   In the most extreme cases 
amputations can occur.  Lower extremity PAD remains one of the most unrecognized 
manifestations of systemic arteriosclerosis estimated to affect  between 3% and 7% of the 
population and up to one in five patients above the age of 75.1  Approximately 15-30% of 
patients with lower extremity PA D will progress from intermitte nt claudication to critical limb 
ischemia (CLI) over the course of their disease.2,[ADDRESS_415760] 
endovascular treatment strategy for symptomatic patients with a therosclerotic disease of the 
superficial femoral (SFA) and popliteal arteries.[ADDRESS_415761]-line  therapy to treat patients with  PAD.5  
Per the current TASC guidelines (TASC II)6balloon angioplasty (Percutaneous Transluminal 
Angioplasty or PTA) is recommend ed as the primary option for en dovascular treatment of 
symptomatic femoropopliteal lesi ons (TASC II A an d B lesions).  Generally, angioplasty (PTA) is 
the preferred initial treatment in patients with disabling clau dication or femoropopliteal 
stenosis or occlusion and in those with chronic critical ischem ia and a stenosis.7  This is 
primarily because PTA is less in vasive and has lower morbidity and mortality risks than 
by[CONTACT_4897].  The use of stent s is reserved for salvage ther apy when balloon dilations is 
suboptimal or fails.8 
1 Davies M, Waldman D, Peterson T. Comprehensive Endovascular Th erapy for Femoropopi[INVESTIGATOR_336487] 
Â‹Â•Â‡ÂƒÂ•Â‡Ç¤
ÂÂ‘ÂÂÂ—Â”Â‰Ç¤Í´Í²Í²Í·Ç¢Í´Í²Í³È‹Í´ÈŒÇ£Í´Í¹Í· -96. 
2 Dormandy J, Mahir M, Ascady G., Balsano F, De Leeuw P, Blomber g P, Bousser MG, Clement D, Coffman J, Deutschinoff A, et al.  Fate of 
Â–ÂŠÂ‡Â’ÂƒÂ–Â‹Â‡ÂÂ–Â™Â‹Â–ÂŠÂ…ÂŠÂ”Â‘ÂÂ‹Â…ÂÂ‡Â‰Â‹Â•Â…ÂŠÂ‡ÂÂ‹ÂƒÇ£ÂƒÂ”Â‡Â˜Â‹Â‡Â™ÂƒÂ”Â–Â‹Â…ÂÂ‡Ç¤
ÂƒÂ” Â†Â‹Â‘Â˜ÂƒÂ•Â…È‹Â‘Â”Â‹ÂÂ‘ÈŒÇ¤Í³Í»ÍºÍ»Ç¢ÍµÍ²Ç£Í·Í² -57. 
3 McDaniel MD, Cronenwett JL.  Basic data related to the natural  history of intermittent claudication.  Ann Vasc Â—Â”Â‰Ç¤Í³Í»ÍºÍ»Ç¢ÍµÇ£Í´Í¹Íµ -277. 
[ADDRESS_415762] R, Ansel G, Lansky A, Cristea E, Collins TJ, Gold stein J, Jaff 
Ç¢ÂÂ˜Â‡Â•Â–Â‹Â‰ÂƒÂ–Â‘Â”Â•Ç¤Â‹Â–Â‹ÂÂ‘ÂÂ•Â–Â‡ÂÂ–Â‹ÂÂ’ÂÂƒÂÂ–ÂƒÂ–Â‹Â‘ÂÂ˜Â‡Â”Â•Â—Â• Â„ÂƒÂÂÂ‘Â‘ÂÂƒÂÂ‰Â‹Â‘Â’ÂÂƒÂ•Â–Â›ÂˆÂ‘Â”ÂÂ‡Â•Â‹ ons in the superficial femoral artery and 
proximal popliteal artery: twelve- ÂÂ‘ÂÂ–ÂŠÂ”Â‡Â•Â—ÂÂ–Â•ÂˆÂ”Â‘ÂÂ–ÂŠÂ‡Â”ÂƒÂÂ†Â‘ÂÂ‹ÂœÂ‡Â†Â–Â”Â‹ÂƒÂÇ¤Â‹Â”Â…ÂƒÂ”Â†Â‹Â‘Â˜ ÂƒÂ•Â…ÂÂ–Â‡Â”Â˜Ç¤Í´Í²Í³Í²Ç¢ÍµÇ£Í´Í¸Í¹ -76. 
5 Zeller T. Current State of Endovascular Treatment of Femoro-Po plital Artery Disease. Vas Â…Â‡Â†Ç¤Í´Í²Í²ÍºÇ¢Í³Í´Ç£Í´Í´Íµ -34. 
6 Zeller T. Current State of Endovascular Treatment of Femoro- Â‘Â’ÂÂ‹Â–ÂƒÂÂ”Â–Â‡Â”Â›Â‹Â•Â‡ÂƒÂ•Â‡Ç¤ÂƒÂ•Â…Â‡Â†Ç¤Í´Í²Í²ÍºÇ¢Í³Í´Ç£Í´Í´Íµ -34. 
7 Hunink MG, Wong JB, Donaldson MC, Meyerovitz MF, de Vries JA, Harrington DP. Revascularization for femoropopliteal disease: a  
decision and cost- Â‡ÂˆÂˆÂ‡Â…Â–Â‹Â˜Â‡ÂÂ‡Â•Â•ÂƒÂÂƒÂÂ›Â•Â‹Â•Ç¤
Ç¤Í³Í»Í»Í·Ç¢Í´Í¹Í¶È‹Í´ÈŒÇ£Í³Í¸Í· -171.
[ADDRESS_415763] Long-Term Outcome After Paclitaxel-Coated  Balloon Angioplasty: An Additional Analysis From the THUNDER 
Â–Â—Â†Â›Ç¤
ÂÂ†Â‘Â˜ÂƒÂ•Â…ÂŠÂ‡Â”Ç¤Í´Í²Í³ÍµÇ¢Í´Í²Ç£Í¹Í»Í´ -800. 
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 16 of 6Íµ 
To understand the effe ctiveness of PTA alone, a full literature  review was conducted by [CONTACT_336519]. Information was compi[INVESTIGATOR_336488], meta-a nalyses and more recent 
randomized controlled trials where PTA was often the control gr oup in peripheral stent device 
trials.  While there was great i nconsistency in the type of dat a reported and the outcomes 
measured, typi[INVESTIGATOR_336489].  Primary pate ncy was considered reported 
when at a minimum the study defined it as maintenance of hemody namic and symptomatic 
improvement after angioplasty wi thout further intervention.  Th e review of PTA results 
determined that while primary pa tency at early time periods was  high (71%-91% at 6 months) 
the longer term results decrease d progressively over time begin ning at one year (0%-87%) 
through five years (38%-62%).  A similar review was conducted o n PTA completed with drug-
coated balloons (DCBs).  This assessment determined that there are improved patency rates 
with the use of Â•Â™ÂŠÂ‹Â…ÂŠÂ™Â‡Â”Â‡ÂÂ‘Â•Â–Â’Â”Â‘ÂÂ‘Â—ÂÂ…Â‡Â†ÂƒÂ–Â–ÂŠÂ‡Í¸ÂÂ‘ÂÂ–ÂŠÂ–Â‹ÂÂ‡Â’Â‘Â‹ÂÂ–È‹Í¹Í´Î¨ Â˜Â•Í¶Í»Î¨Ç¢
DCB vs PTA), but were maintained through one year (65.2%-67% vs  52.6%-Í·Í·Î¨Ç¢Â˜Â•ÈŒ
ÂƒÂÂ†Â–Â™Â‘Â›Â‡ÂƒÂ”Â•È‹Í·Í¹Î¨Â˜Â•Í¶Í²Î¨Ç¢Â˜Â•ÈŒÇ¤  
As with all medical interventions, there are risks associated w ith the use of PTA in the 
femoropopliteal arteries that may lead to sub-optimal results a nd likely contribute to the large 
range associated with efficacy results.  The guidelines and cli nical research do not provide a 
clear definition of angioplasty failure, however one cause of s uboptimal results is post-PTA 
arterial dissection.  Limited information is available on the e ffect of dissection on angiographic 
and clinical outcomes after peripheral artery interventions.  O ne reason for the lack of 
reported data in peripheral studies is that much of the methodo logy and approaches for 
treating dissections were initia lly developed within the practi ce of coronary angioplasty.  The 
techniques and practices developed in the coronary field were a dopted over to peripheral PTA.  
At this time, there is no peripheral specific system available for classification of post-PTA 
dissections and no defin ed treatment paradigms. 
In order to determine the incidence and characteristics of peri pheral dissections, the 
associated literature related to  femoropopliteal PTA was invest igated in detail.  The reported 
rates for dissection as assessed either through angiographic as sessment or IVUS was 7.4%-
88%.  In some instances, the appr oach to treat dissections is u se of â€œBailoutâ€ stents.  Reported 
rationale for their use in the f emoropopliteal segments are for  suboptimal angiographic result 
or flow-limiting dissection and their reported use ranges from 6%-72.9%.  In an additional 
analysis comparing the use of DC B to standard PTA, similar resu lts were noted.  The rate of 
dissection in comparative trials reported ranged from 19%-63.7%  in DCB cases and 18%-
73.5% of PTA cases and bail-out stenting for dissection was per formed at a rate of 2.5%-8.9% 
for DCB and 6.9%-14.3% for PTA.   Bailout stenting was typi[INVESTIGATOR_336490] 
ÂÂ‹Â–Â‹ÂÂ‘ÂÂ•Â–Â‡ÂÂ–Â•Ç¢ÂŠÂ‘Â™Â‡Â˜Â‡Â”Â–ÂŠÂ‡Â–Â› Â’Â‡Â™ÂƒÂ•Â‰Â‡ÂÂ‡Â”ÂƒÂÂÂ›ÂÂ‘Â–Â†Â‡ÂˆÂ‹ÂÂ‡Â†Ç¤  
Two studies were identified that discussed the incidence of dis sections and associated clinical 
implications in the peripheral vasculature in more detail.  Fir st is the EPI[INVESTIGATOR_336491].9,[ADDRESS_415764] whether a patient is likelyâ€”or notâ€”to have a long-term,  event-free outcome.  Per the 
9 Gussenhoven EJ, van der Lugt A, Pasterkamp G, van den Berg FG,  Sie LH, Vischjager M, The SHK, Li W, Pi[INVESTIGATOR_336492] H, can Urk H. 
ÂÂ–Â”ÂƒÂ˜ÂƒÂ•Â…Â—ÂÂƒÂ”ÂÂ–Â”ÂƒÂ•Â‘Â—ÂÂ†Â”Â‡Â†Â‹Â…Â–Â‘Â”Â•Â‘ÂˆÂ—Â–Â…Â‘ÂÂ‡Â•ÂˆÂ–Â‡Â”Â‡Â”Â‹Â’ÂŠÂ‡Â”Âƒ ÂÂƒÂÂÂ‘Â‘ÂÂÂ‰Â‹Â‘Â’ÂÂƒÂ•Â–Â›Ç¤Â—Â”
ÂÂ†Â‘Â˜ÂƒÂ•Â…Â—Â”Â‰Ç¤Í³Í»Í»Í·Ç¢Í³Í²Ç£Í´Í¹Í» -288. 
[ADDRESS_415765] of Balloon Angioplasty in 
	Â‡ÂÂ‘Â”Â‘Â’Â‘Â’ÂÂ‹Â–Â‡ÂƒÂÂ”Â–Â‡Â”Â‹Â‡Â•Â•Â•Â‡Â•Â•Â‡Â†Â„Â›ÂÂ–Â”ÂƒÂ˜ÂƒÂ•Â…Â—ÂÂƒÂ”ÂÂ–Â”ÂƒÂ•Â‘Â—ÂÂ†Ç¤ Â—Â”
ÂÂ†Â‘Â˜ÂƒÂ•Â…Â—Â”Â‰Ç¤Í³Í»Í»Í¹Ç¢Í³ÍµÇ£Í·Í¶Í» -556
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 17 of 6Íµ 
authors â€œFailure is more likely to occur in the presence of a l arge dissection and a small 
residual free lumen area and dia meter evidenced following PTA.â€11   A follow-up study 
investigated the potential role of intravascular ultrasound (IV US) in assessing the outcome in 
patients undergoing percutaneous transluminal angioplasty (PTA)  of the superficial femoral 
artery.  After PTA, vascular dam age was seen at the target site  in 72% of arteries, plaque 
rupture in 26%, dissection in 57%(45% of all cross sections and  88% in all dilated segments) 
and media rupture in 17%.   
The second study to be discussed  in detail is the THUNDER trial .12  The THUNDER trial was a 
prospective, randomized double-blinded controlled German multic enter study on the efficacy 
of local paclitaxel delivered by a drug coated balloon for prev ention of restenosis in the 
superficial femoral and poplitea l arteries.  The study performe d an analysis of outcomes after 
dissection.  Within the study, t he overall rate o f dissection w ith PTA intervention was 56%.  
Note that stents were to be used in cases of residual stenosis (>50%) or in the case of flow-
limiting dissection.  There were  two cases of flow limiting dis section and in each case stents 
were placed.  In all other cases of non-flow-limiting dissectio ns, no additional interventions 
were performed.   
For analysis of outcomes after dissection, the THUNDER data wer e reviewed by a blinded and 
independent core lab.  The lab used the National Heart, Lung an d Blood Institute (NHBLI) 
classification system for intimal tears (applies to angiographi c assessments).  This system 
which was developed by [CONTACT_336520] A to F 
based on angiographic appearance .  The dissection rates by [CONTACT_336521] 1 . 
Table 1: Femoropopliteal Dissecti on-THUNDER Trial Reported Rates 
Dissection Type Percentage 
A13 12%
B 52%
C 6% 
D 28%
E 2% 
F14 0% 
Similar results were observed in a clinical trial conducted by [CONTACT_336514]. The TOBA study 
was conducted in Europe to collect confirmatory data in support  of the safety and performance 
of the Intact Vascular Tack Endovascular Systemâ„¢.  In the study , operators routinely 
underestimated the severity of d issections.  In each instance, dissections were reported by [CONTACT_336522]-treatment documentation.  Each angiogram underwent  a post-procedure review 
by [CONTACT_50305].  A c omparison of the site reported data and the core lab reported 
data for dissections is presented in Table 2 . 
11Gussenhoven EJ, van der Lugt A, Pasterkamp G, van den Berg FG, Sie LH, Vischjager M, The SHK, Li W, Pi[INVESTIGATOR_336492] H, can Urk H. 
ÂÂ–Â”ÂƒÂ˜ÂƒÂ•Â…Â—ÂÂƒÂ”ÂÂ–Â”ÂƒÂ•Â‘Â—ÂÂ†Â”Â‡Â†Â‹Â…Â–Â‘Â”Â•Â‘ÂˆÂ—Â–Â…Â‘ÂÂ‡Â•ÂˆÂ–Â‡Â”Â‡Â”Â‹Â’ÂŠÂ‡Â”Âƒ ÂÂƒÂÂÂ‘Â‘ÂÂÂ‰Â‹Â‘Â’ÂÂƒÂ•Â–Â›Ç¤Â—Â”
ÂÂ†Â‘Â˜ÂƒÂ•Â…Â—Â”Â‰Ç¤Í³Í»Í»Í·Ç¢Í³Í²Ç£Í´Í¹Í» -288. 
[ADDRESS_415766] Long-Term Outcome After Paclitaxel-Coated  Balloon Angioplasty: An Additional Analysis From the THUNDER 
Â–Â—Â†Â›Ç¤
ÂÂ†Â‘Â˜ÂƒÂ•Â…ÂŠÂ‡Â”Ç¤Í´Í²Í³ÍµÇ¢Í´Í²Ç£Í¹Í»Í´ -800. 
13 Approximated from study tables 
14 There were two cases of flow- ÂÂ‹ÂÂ‹Â–Â‹ÂÂ‰Â†Â‹Â•Â•Â‡Â…Â–Â‹Â‘ÂÂ‹ÂÂ–ÂŠÂ‡Â•Â–Â—Â†Â›Â’Â‘Â’Â—ÂÂƒÂ–Â‹Â‘ÂÇ¢ÂŠÂ‘Â™Â‡Â˜Â‡Â”Â–ÂŠÂ‡Â›Â™Â‡Â”Â‡ ÂÂ‘Â–Â‹ÂÂ…ÂÂ—Â†Â‡Â†Â‹ÂÂ–ÂŠÂ‡ÂƒÂ•Â•Â‡Â•Â•ÂÂ‡ÂÂ–ÂƒÂ•Â‹ÂÂ‡ÂƒÂ…ÂŠ
case they were treated with a stent
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 18 of 6Íµ 
Table 2: Femoropopliteal Dissec tionsâ€”TOBA Reported Results 
Dissection 
Type Site Reported 
(n=128) Core Lab Reported 
(n=127) 
Number Percentage Number Percentage 
A 56 43.8% 6 4.7% 
B 38 29.7% 24 18.9% 
C 21 16.4% 79 62.2% 
D 9 7.0% 15 11.8% 
E 3 2.3% 0 0.0% 
None 1 0.8% 3 2.4% 
The findings were consistent with the THUNDER study and demonst rate, that dissections are 
often worse than they are observ ed at the time of the intervent ion.  In this instance, the 
ÂÂƒÂŒÂ‘Â”Â‹Â–Â›Â‘ÂˆÂ•Â‹Â–Â‡Â”Â‡Â’Â‘Â”Â–Â‡Â†Â†Â‹Â•Â•Â‡Â… Â–Â‹Â‘ÂÂ•Â™Â‡Â”Â‡
Â”ÂƒÂ†Â‡Â‘Â”Ç¢ÂŠÂ‘Â™Â‡Â˜Â‡ Â”ÂƒÂˆÂ–Â‡Â”Â‘Â”Â‡  Lab evaluation, 
they were often higher grade. In  fact, the operator reported da ta only reported 25.7% grade C 
or higher dissections in contras t to the 74% value determined b y the core lab. 
To fully understand the impact of post-PTA dissections, investi gation is required on their 
associated potential clinical im plications.  Because of higher incidence of complications due to 
dissections, their impact on cli nical outcome has been an impor tant issue in percutaneous 
coronary interventions.  More se vere dissections seem to be ass ociated with higher restenosis 
rates and early occlusions.[ADDRESS_415767] comprehensive assessment of clinical implications in 
the peripheral vasculature was the previously discussed in the THUNDER study.  Angiographic 
analysis of study patients inclu ded angiograms from before and after the intervention and 
from the 6-month follow-up.  The primary clinical outcome was T LR at 6- and 24- month time 
points.  The parameters assessment were late lumen loss (LLL), minimum lumen diameter 
(MLD) and an area anal ysis to evaluate the entire longitudinal luminal area of the vessel 
dilated.  There were no significa nt differences in the post-pro cedure angiographic parameters 
between patients with grades A or B dissection vs. grade C, D, or E (although the degree of 
residual stenosis (Narrowing) te nded to be larger with higher g rade dissections). 
The THUNDER study concluded that untreated dissections were obs erved to be correlated 
with increased complications and  with decreased long-term paten cy.  For all dissection grades, 
clinical implications were noted  in patients with observed diss ections.  To further understand 
the implications, the literature  results were reviewed and comp iled to compare to the extent 
possible the clinical/angiographic results of PTA with no post- procedure dissections (from 
general literature references) t o those of post-PTA dissection (from the THUNDER Trial) in the 
femoropopliteal arteries.  Only one time period had defined dat a for both subsets (6 months).  
These results are summarized in Table 3 .  
Table 3: Comparison of 6 month Angiographic Data 
PTA16 Dissection 
Grade A/B Dissection 
Grade 
C/D/E All 
Dissection 
[ADDRESS_415768] Long-Term Outcome After Paclitaxel-Coated  Balloon Angioplasty: An Additional Analysis From the THUNDER 
Â–Â—Â†Â›Ç¤
ÂÂ†Â‘Â˜ÂƒÂ•Â…ÂŠÂ‡Â”Ç¤Í´Í²Í³ÍµÇ¢Í´Í²Ç£Í¹Í»Í´ -800. 
16 PTA without noted dissection per literature references 
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 19 of 6Íµ 
Binary restenosis17 43%18 50% 62% 55% 
Patency (extrapolated 
from restenosis data) 71%-91% 50% 38% 45% 
Late Lumen Loss (mm) NA 1.6Â±1.7 2.4Â±1.78 1.9Â±1.7 
Target Lesion 
Revascularization 10.5% 33% 44% 37% 
The results in Table [ADDRESS_415769] that even with low grade dissections (Type A/B) clinica l 
implications may be observed with lower patency rates than thos e observed for PTA and 
higher rates of TLR when compared to PTA without dissections.  While these results are more 
pronounced for C/D/E dissections, the clinical impact of all di ssections is notable.  Primary 
patency was lower and target lesion revascularization higher fo r the patient population with 
observed dissections.   
Based on the clinical and litera ture reported data indicative o f an under-reporting of higher 
grade dissections and the clinical links to observed lower pate ncy rates, there exists a clinical 
need to provide for fo cal treatment of post-PTA non-flow-limiti ng dissections in addition to 
those that are flow-limiting.  The Tack Endovascular System is designed to provide a treatment 
option for all grade dissections. 
INVESTIGATIONAL DEVICE  
5.1. D ESCRIPTION  
The Tack Endovascular System is an endovascular device system d esigned to treat vascular 
dissections with Tack implants  following angioplasty in the su perficial femoral and proximal 
popliteal arteries, ranging 2.5 mm to 6.0 mm in diameter.  The 6F (2.0 mm) catheter contains 6 
independent self-expanding Tacks made of a nickel titanium allo y (Nitinol).  When deployed, 
the Tack implants are designed t o treat acute dissections of th e inner wall or lining of an artery 
by [CONTACT_336523] a low outward radial force. 
The Tack Endovascular System consists of 6 self-expanding Nitin ol Tacks and a 6F Delivery 
Catheter (See Figure 1 ). The numbers in parentheses in the following section refer th ose in 
Figure [ADDRESS_415770] Class 4-6 which would likely correlate wi th a 
higher restenosis rate
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 20 of 6Íµ 
The Tacks are approxim ately 6mm in length an d expand to an unco nstrained diameter of 7.3 
mm (See Table 4  below). The Tack implants are designed with a relatively flat chronic 
outward force curve and may be u sed across all reference vessel  diameters (RVDs) ranging 
from 2.5 to 6.0mm. Six Radiopaqu e (RO) Markers (16) as well as six pairs of Anchors (17) are 
located around the centerline of  each Tack implant. The anchors  assist in maintaining proper 
Tack implant position. 
Table 4. Tack Length at Various Diameters  
Diameter Length 
1.8 mm (Constrained Tack) 6.5 mm 
2.5 mm RVD  (Deployed Tack) 6.4 mm 
6.0 mm RVD (Deployed Tack) 6.2 mm 
7.3 mm (Unconstrained Tack) 6.1 mm

TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 21 of 6Íµ 
The delivery catheter has an effective length of 120cm. The 6F Outer Braided Sheath (7), which 
constrains the Tack im plants, is bonded proximally to the Bifur cation Luer (9) within the 
Strain Relief (8). The Hemostatic Valve (11) is integrated prox imally to the Bifurcation Luer. 
The Inner Core Shaft (3) slides within the Hemostatic Valve and  has seven Proximal Inner Core 
Markers (13). The number of visi ble reference marks corresponds  to the number of 
undeployed Tack implants remaini ng in the distal end of the del ivery system.  A soft, tapered 
Distal Tip (2) is bonded to the distal end of the Inner Core Sh aft for ease of ad vancement in the 
blood vessel. Constrained within the Outer Braided Sheath, each  self-expanding Tack implant 
is positioned on the Inner Core Shaft (3) between two radiopaqu e Distal Inner Core Markers 
(4) spaced approximately 7mm apar t. A 1mm radiopaque Target Ban d (6) is located on the 
distal end of the Outer Braided Sheath.  
The catheter is flushed prior to the procedure through the side  port of the Bifurcation Luer and 
the Guidewire Port. Tack implant  positioning is achieved prior to deployment by [CONTACT_336524].  
During Tack implant deployment Ç¢ the Hemostatic Valve is unlocked by [CONTACT_336525]-clockwise. The Tack implants are individually unsheathe d by [CONTACT_21173][INVESTIGATOR_336493] k on the outer sheath the dista nce between proximal inner 
core markers.  After each deployment, the Hemostatic Valve is l ocked by [CONTACT_336526], ensuring that the pro ximal edge of the Target Band i s secured directly over a Distal 
Inner Core Marker. Between deplo yments, both the proximal inner  core markers and the distal 
inner core markers serve to visually represent the number of re maining Tack implants in the 
delivery catheter. 
5.2. P RINCIPLES OF OPERATION  
A peripheral intervention of the lower extremity arteries, such  as balloon angioplasty to treat 
stenotic or occluded arteries is performed, which would include  dilatation of the artery at the 
target site to its full intended  arterial diamet er. A post-PTA angiogram is done to assess the 
results of the angioplasty.  If optimal angioplasty results are  not achieved due to one or more 
dissections in a lesion with less than 30% residual diameter st enosis (DS), the patient may be a 
candidate for treatment with t he Tack Endovascular System. 
Once a treatment area has been identified for the Tack Endovasc ular System, a 0.035â€ 
guidewire is inserted into the 6 F percutaneous angiographic she ath and advanced to the 
targeted treatment site. The delivery catheter is then advanced  to the treatment site using 
fluoroscopic guidance. Each Tack is deployed independently at t he desired location by 
[CONTACT_336527].  
Note: For a full device and proce dural description, please refe r to the Instructions for Use 
(IFU). 
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 22 of 6Íµ 
5.3. I NTENDED USE
The Tack Endovascular System is intended for use in the superfi cial femoral and proximal 
popliteal arteries ranging in diameter from 2.5mm to 6.0mm for the repair of post 
percutaneous transluminal balloon angioplasty dissection(s) typ e(s) A through F.  
CLINICAL STUDY OBJECTIVES  
6.1. P RIMARY ENDPOINTS  
Safety:  Freedom from the occurrence of an y new-onset major adverse even t(s) (MAEs) defined 
as index limb amputation (above the ankle), CEC adjudicated cli nically-driven target lesion 
revascularization (CD-TLR), or all-cause death at 30 days. 
Efficacy : Primary patency defined as freedom from CEC adjudicated clinica lly-driven target 
lesion revascularization (CD-TLR) and freedom from core lab adj udicated duplex ultrasound 
derived binary restenosis at 12 months (defined as PSVR >2.5). 
6.2. O BSERVATIONAL ENDPOINTS
Device Success: Successful deployment of the Tack(s) at the int ended target site(s) and 
successful withdrawal of the delivery catheter. If the study de vice is introduced but the subject 
does not receive a Tack due to user error and not a device malf unction, this device will not be 
included in the device success assessment. 
Procedural Success: Demonstrated vessel patency (<30% residual DS, by [CONTACT_13729]) 
w i t h o u t  t h e  u s e  o f  a  b a i l o u t  s t e n t  o r  t h e  o c c u r r e n c e  o f  M A E  u p o n completion of the index 
procedure. 
The following will be assessed through 36 months: 
ÂƒAll-cause death
ÂƒAmputation of the target  limb (above the ankle)
ÂƒClinically-driven target vessel revascularization (CD-TVR)
ÂƒClinically-driven target lesion revascularization (CD-TLR)
ÂƒTarget vessel revascularization (TVR)
ÂƒTarget lesion revascularization (TLR)
ÂƒChanges from Baseline in R utherford Classification
ÂƒChanges from Baseline in Ankle Brachial Index (ABI) measurement
ÂƒChanges from Baseline in the Peripheral Artery Questionnaire (P AQ)
ÂƒChanges from Baseline in the EQ- 5D-3L quality of life questionn aire
ÂƒChanges from Baseline in the Walking Impairment Questionnaire ( WIQ)
ÂƒTack Integrity via X-ray (only performed at 12 month visit)
ÂƒD u p l e x  U l t r a s o u n d  ( D U S )  d e r i v e d  l e s i o n  a n d  v e s s e l  p a t e n c y  ( p e r f ormed at each visit
through 12 months)
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 23 of 6Íµ 
CLINICAL STUDY DESIGN  
This is a prospective, multi-center, single-arm, non-blinded st udy designed to investigate the safety 
and efficacy of the Tack Endovascular System in subjects with p ost-balloon angioplasty (post-PTA) 
dissection(s) type(s) A through F in the superficial femoral an d proximal popliteal arteries ranging 
in diameter from 2.5mm to 6.0mm. 
7.1. I NVESTIGATIONAL SITES
Subjects will be enrolled at up to 40 clinical sites throughout  the [LOCATION_002] and Europe (up 
to 5 European sites will participate). 
7.2. S UBJECT POPULATION  
Subjects with PAD who receive PTA (with a standard or FDA-appro ved Lutonix drug-coated 
balloon) in the SFA and proximal popliteal (P1) a rteries and ha ve a resulting dissection(s) 
type(s) A through F are eligible for enrollment. To be enrolled , subjects must meet all inclusion 
criteria and not meet any of the exclusion criteria. 
7.3. A NTICIPATED NUMBER OF SUBJECTS  
It is anticipated that up to 210 subjects will be enrolled. Eac h clinical site can enroll a 
maximum of 53 patients, establishing an enrollment cap at 25% o f the subject sample size. 
Intact Vascular will continuously monitor each enrolled subject  receiving study device 
treatment following PTA with a standard balloon or the FDA-appr oved Lutonix drug-coated 
balloon (DCB). Treatment with a T ack following PTA with a DCB s hall not exceed 60% of 
subjects enrolled. 
7.4. C LINICAL STUDY DURATION & FOLLOW -UP 
The follow-up duration for each enrolled subject is [ADDRESS_415771] one Tack implant will be followed for  12 months and then exited from 
the study (see Section 10.3.1 ). 
7.5. S UBJECT SELECTION  
7.5.1. I NCLUSION CRITERIA  
Subjects must meet all the following Inclusion Criteria. The re sponse for each criterion 
below must be â€œYesâ€:  
1. Male or non-pregnant Female Î· [ADDRESS_415772] use some form of contraception (abstinence i s acceptable) through
the duration of the study
3. Target limb requires no additional treatment aside from the t arget lesion and the iliac
artery(ies) during the index procedure
[ADDRESS_415773]
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 24 of 6Íµ 
5. Willing to comply with all required follow-up visits
6. Rutherford Classification 2, 3 or 4
7. Estimated life expectancy >[ADDRESS_415774] is ambulatory (assistive devices such as a cane or wa lker is acceptable).
7.5.2. A NGIOGRAPHIC INCLUSION CRITERIA  
Subjects must meet all the following Angiographic Inclusion Cri teria. The response for each 
criterion below must be â€œYesâ€:  
1. Reference vessel diameter is between 2.5 mm and 6.0 mm, inclu sive (by [CONTACT_13729]),
and able to be treated wit h the Study Device implant
2. Ability to cross a guidewire ( antegrade) through target lesio n
3. Has a de novo or non-stented r estenotic target lesion indicat ed for PTA treatment with a
standard or FDA-approved Lutonix drug-coated balloon catheter t hat meets the following 
criteria below:
a. 70% to 99% stenosis with a total lesion length of Î·Í´Í²ÂÂÂƒÂÂ†Î¶Í³Í·Í²ÂÂÂ‹ÂÂÂ‡ÂÂ‰Â–ÂŠ
È‹Â„Â›Â˜Â‹Â•Â—ÂƒÂÂ‡Â•Â–Â‹ÂÂƒÂ–Â‡ÈŒÂ‘Â”Ç¢
b. 100% occluded with a t otal lesion length Î¶100mm (by [CONTACT_13729])
Notes:
A tandem lesion, defined as a lesion comprised of diseased and healthy segments,
is eligible if the healthy segments are each not more than 30mm  in length and all
other criteria, including 3a and 3b above, are met
A combination lesion, defined as a continuous lesion with both non-occluded and
100% occluded segments, is eligible if the lesion can be treate d as a single lesion
and all other criteria, including 3a and 3b above, are met
c. A non-stented restenotic lesion must meet the following crite ria:
i. Meets criter ia 3a and 3b
i i . N o  p a r t  o f  t h e  t a r g e t  l e s i o n  h a s  b e e n  p r e v i o u s l y  t r e a t e d  w i t h a drug-
coated balloon
iii. No part of the target lesion has had more than 2 previous P TA failures
iv. >[ADDRESS_415775] recent angioplasty treatment
4. Target lesion is in the superficial femoral artery (SFA) and/ or proximal popliteal artery
È‹ÂƒÂ„Â‘Â˜Â‡Â–ÂŠÂ‡ÂÂÂ‡Â‡ÈŒÇ¡ÂÂ‘Â…ÂƒÂ–Â‡Â†Î·Í³Â…Â Â„Â‡ÂÂ‘Â™Â–ÂŠÂ‡Â…Â‘ÂÂÂ‘ÂÂˆÂ‡ÂÂ‘Â”ÂƒÂÂƒÂ”Â–Â‡Â”Â› È‹	ÈŒÂ„Â‹ÂˆÂ—Â”Â…ÂƒÂ–Â‹Â‘ÂÂ–Â‘
the distal segment of the proxim al popliteal (P1) artery at the  superior end of the patella
5. Presence of at least one patent (<50% DS) infrapopliteal vess el that has not been
revascularized prior to index procedure
6. After PTA treatment, the targe t lesion has <30% residual DS and presence of at least one
post-PTA dissection (Type A-F) (by [CONTACT_13729])
7. No evidence of aneurysm or acute thrombus in target vessel
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 25 of 6Íµ 
7.5.3. E XCLUSION CRITERIA  
Subjects must not meet any of the following Exclusion Criteria.  The response for each 
criterion below must be â€œNoâ€:  
1. Rutherford Classification 0, 1, 5 or 6
2. Is pregnant or refuses to use contraception through the durat ion of the study
3. Previous infrainguinal by[CONTACT_336516]
4. Planned amputation on the target limb
5. Systemic infection or Infection within the target limb and/or  immunocompromised
6. Endovascular or surgical procedure (not including diagnostic procedures) on the target
limb within 30 days prior to or within 30 days after the index procedure
7. Endovascular or surgical procedure (not including diagnostic procedures) on the non-
target limb within 14 days prior to the index procedure or plan ned procedure within 30
days after the index procedure
8. Prior coronary artery by[CONTACT_6476] g raft (CABG) or percutaneous cor onary intervention (PCI)
procedure within 30 days prior t o the index procedure or planne d CABG/PCI within 30
days after the index procedure
9. Any other previous or planned surgical or endovascular proced ure (not including
diagnostic procedures) within [ADDRESS_415776] index procedure
10. Planned atherectomy, cryoplasty, stenting or any other treat ment (with the exception of
a crossing device) of the target  lesion other than PTA during t he index procedure
11. Known coagulopathy, hypercoag ulable state, bleeding diathesi s, other blood disorder,
or a platelet count less than 80,000/microliter or greater than  500,000/microliter.
12. Known hypersensitivity or allergy to  antiplatelet or antico agulant therapy
13. Myocardial infarction within 30 days prior to enrollment
14. History of stroke within 90 days prior to enrollment15. Serum creatinine of >2.5 mg/dL
16. Requires treatment of tibial or outflow vessels at the index  procedure, which include the
P2 and P3 segments of the poplit eal artery and the tibioperonea l vessels.
17. Known hypersensitivity or contraindication to nickel-t itanium alloy (Nitinol)
18. Participating in another ongoing investigational clinical tr ial that has not completed its
primary endpoint
1 9 . H a s  o t h e r  c o m o r b i d i t i e s  t h a t ,  i n  t h e  o p i n i o n  o f  t h e  i n v e s t i g ator, would preclude them
f r o m  r e c e i v i n g  t h i s  t r e a t m e n t  a n d / o r  p a r t i c i p a t i n g  i n  s t u d y - r e q uired follow-up
assessments
20. Known hypersensitivity or alle rgy to contrast agents that ca nnot be medically managed
21. Thrombolysis of the target vessel within 72 hours prior to t he index procedure, where
complete resolution of the thrombus was not achieved
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 26 of 6Íµ 
7.5.4. A NGIOGRAPHIC EXCLUSION CRITERIA  
Subjects must not meet any of th e following Angiographic Exclus ion Criteria. The response 
for each criterion below must be â€œNoâ€:  
1. Retrograde crossing through target lesion
2. Acute vessel occlusion or acute or sub-acute thrombosis in ta rget lesion
3. Subject has significant stenosis ( Î·50% stenosis) or occlusion of ipsilateral inflow iliac
artery not successfully treated (<30% residual DS and without c omplication) prior to
PTA of target vessel
4. Angiographic evidence of calci fication severe enough that it renders the target lesion
non-Â†Â‹ÂÂƒÂ–ÂƒÂ„ÂÂ‡ÂƒÂÂ†È€Â‘Â”ÂŠÂƒÂ•Î·Í·Â…ÂÈ‹Â˜Â‹Â•Â— ÂƒÂÂ‡Â•Â–Â‹ÂÂƒÂ–Â‡ÈŒÂ‘ÂˆÂ…Â‹Â”Â…Â—ÂÂˆÂ‡Â”Â‡ÂÂ–Â‹ÂƒÂ calcification
5. The target lesion shows no dissections after PTA
6.Â”Â‡Â•Â‡ÂÂ…Â‡Â‘ÂˆÂ”Â‡Â•Â‹Â†Â—ÂƒÂÂ†Â‹ÂƒÂÂ‡Â–Â‡Â”Â•Â–Â‡ÂÂ‘Â•Â‹Â•Î·ÍµÍ²Î¨ÂƒÂˆÂ–Â‡Â”È‹Â„ÂƒÂ•Â‡Â†Â‘Â Â˜Â‹Â•Â—ÂƒÂÂ‡Â•Â–Â‹ÂÂƒÂ–Â‡ÈŒ
7. Non-target limb requiring any vascular treatment at time of i ndex procedure
8. Previously implanted ste nt in the target vessel
TREATMENT PLAN 
8.1. T IME AND EVENTS SCHEDULE  
All subjects will rece ive the assessments at  specific time poin ts as listed in Table 5  below. 
Table 5. Time and Events Schedule 
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 27 of 6Íµ 
Assessment 
Baseline1 
Implant 
Procedure 
Pre-Discharge 
30-day 
(-2 days/ 
+14 Da ys) 
6 
Month 
(Â±30 Days) 
12 
Month 
(Â± 30 Days) 
24 
Month 
(Â± 30 Days) 
36 
Month 
(Â± 30 Days) 
Unscheduled7 
Informed Consent X2 
Medical History / 
Physical Exam  X 
Serum Creatinine X 
PT/ INR3 X 
Urine pregnancy test if female
4 X 
Ankle Brachial Index (ABI) X X10 X X X X X X 
Rutherford Classification X X X X X X X 
Pre-procedural Medications X 
Angiogram X X9 
Study Medications X X X X X X X X 
Duplex Ultrasound (DUS)
5 X X X X9 
X-ray of Implanted Tacks
6 X8 X9 
Adverse Event AssessmentX X X X X X X X 
Peripheral Artery Questionnaire (PAQ)  X X X X X X X 
EQ-5D-3L X X X X X X X 
Walking Impairment Questionnaire (WIQ) X X X X X X X 
[ADDRESS_415777] 
2 Consent to be obtained within 30 days prior to enrollment. 
3 PT/INR to be obtained only if s ubject is on chronic warfarin t herapy. 
[ADDRESS_415778] within 7 days of the Index Proce dure is required for women of childbearing potential. 
5 All scheduled DUS exams should be performed per the protocol e stablished by [CONTACT_50338]. If a DUS is non-diagnostic 
(per the imaging protocol), the site should make every effort t o obtain a repeat exam within the visit window.  
[ADDRESS_415779] d during the index procedure.  
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 28 of 6Íµ 
[ADDRESS_415780]-index pr ocedure. 
NOTE : All imaging of the target limb acquired during scheduled and unscheduled visits (such as Angiogram, DUS or X-
Ray) should be submitted to the respective core lab within 3 da ys of occurrence. 
8.2. P RE-SCREENING  
All subjects presenting to the institution with known superfici al femoral and/or proximal 
popliteal artery disease requiring balloon angioplasty (standar d or drug-coated balloon) will 
be screened for initial eligibility. A trained member of the re search team shall perform a 
preliminary evaluation of the po tential subjectâ€™s medical histo ry and screen for initial 
eligibility. If during the pre-screening the subject is found t o meet one or more exclusion 
criteria, the subject would be considered a â€œpre-screen failure â€. No further action would be 
taken for pre-screen failure sub jects. If determined eligible p er initial inclusion criteria, the 
subject will be approached by [CONTACT_336528].   
8.3. O BTAINING INFORMED CONSENT  
All sites shall comply with 21 CFR 50, provisions of ICH Good C linical Practices (GCPs), local 
IRB/EC policy and all applicable local regulations for obtainin g Informed Consent. Written 
informed consent using the most current IRB/EC-approved informe d consent form (ICF) at the 
time of consent will be obt ained for all subjects prior  to any study-specific screening/baseline 
tests or procedures are performed.  This does not include those  procedures or tests that are 
obtained in the normal course of  the subjectâ€™s non-study relate d care and prior to undergoing 
the study procedure, but shall i nclude previously performed tes ts that may need to be 
repeated in order to det ermine eligibility.   
All subjects shall possess the a bility to understand the inform ation contained in the informed 
consent form. Subjects will have  the study procedures explained  in a manner as non-technical 
as possible, including the risks, benefits and follow-up requir ements. If the subject agrees to 
participate in this study, the subject will personally sign and  date the ICF. In the event that a 
subject possesses the ability to understand the informed consen t process and participation in 
study, but due to physical inabi lity cannot sign the ICF, an im partial witness may sign the ICF 
on behalf of the subject. Non-English speaking subjects may onl y be enrolled if they sign an 
IRB/EC approved and certified tr anslated informed consent form document reflective of 
his/her spoken language. 
Once all required parties have signed the ICF, subjects will re ceive copi[INVESTIGATOR_336494]. 
8.4. S CREENING SUCCESS AND FAILURE CRITERIA  
Final eligibility of a subject will occur during the Index Proc edure. Subjects undergoing an 
angiographic screen must provide prior informed consent.  Every  effort will be made to ensure 
eligibility of the participants prior to enrollment. If no angi ographic exclusion criteria are met 
after pre-enrollment angioplasty, subjects will be considered e ligible for enrollment. If at any 
point prior to or just after pre-enrollment angioplasty, an ang iographic exclusion criteria is 
met, subjects will not be consid ered eligible for enrollment an d will be documented as 
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 29 of 6Íµ 
â€œangiographic screen failuresâ€. No further follow-up will be re quired of these subjects, 
ÂŠÂ‘Â™Â‡Â˜Â‡Â”Ç¢ reason for angiographic failure shall be documented by [CONTACT_336529] a screening log. 
BASELINE EVALUATION  
9.1. B ASELINE ASSESSMENTS  
The following assessments will be performed during baseline eva luation.  These examinations 
and tests will be used both to screen eligible subjects and pro vide baseline information for those 
subjects that meet study criteri a. All assessments must be comp leted within the [ADDRESS_415781] be completed 
within 7 days of the index procedure with a negative result pri or to receiving treatment. 
ÂƒDemographic information and medical history including risk fact ors
ÂƒPhysical examination
oHeight and weight
ÂƒTarget Limb Resting Ankle Brachial Index (ABI)
ÂƒRutherford Classification
ÂƒSerum creatinine ( Î¶Í´Ç¤Í·  mg/dL for inclusion)
ÂƒPT & INR (if on chronic warfarin therapy), PLT count
ÂƒUrine pregnancy test if female of child-bearing age (within 7 days of procedure)
ÂƒPeripheral Artery Questionnaire (PAQ)
ÂƒEQ-5D-3L
ÂƒWalking Impairment Questionnaire (WIQ)
ÂƒConcomitant medications (ant iplatelet/anticoagulants)
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 30 of 6Íµ 
9.2. S TUDY MEDICATIONS  
See Table [ADDRESS_415782] of care if not on chronic antiplatelet therapy N/A 81-325 mg/QD 
indefinitely is recommended 
Thienopyridine Class Agent
[ADDRESS_415783] of care if 
not on chronic antiplatelet 
therapy  N/A 75 mg/QD for a 
minimum of one month 
recommended2 
Heparin Dosage per institutional 
standard of care. Achieve 
anticoagulation per hospi[INVESTIGATOR_307] / institution standard of care
3 N/A 
1 Recommended Thienopyridine class agents incl ude Clopi[INVESTIGATOR_7745], Ticlopi[INVESTIGATOR_336495]. 
2 Recommended daily dose for Clopi[INVESTIGATOR_7745]. Respective regimen should be prescribed for other 
  thienopyridine agents per Investigator discretion. 
3ÂÂ…Â–Â‹Â˜ÂƒÂ–Â‡Â†ÂÂ‘Â–Â–Â‹ÂÂ‰Â‹ÂÂ‡È‹ÈŒÂ‘ÂˆÎ»Í¸Í»Í¶Â•Â‹Â•Â”Â‡Â…Â‘ÂÂÂ‡ÂÂ†Â‡Â†Ç¤  
INDEX PROCEDURE  
10.1. I NDEX BASELINE ANGIOGRAM  
The Index Baseline Angiogram will be performed before Pre-Enrol lment Balloon Angioplasty in 
order to assess baseline angiographic eligibility for inclusion  as described in Section 10.1.2  
below. The angiogram is to be pe rformed as per guidelines estab lished by [CONTACT_336530]. Index procedure angiograms performed for all enroll ed subjects will be reviewed by 
[CONTACT_336531] (including identificatio n of post-PTA dissections and 
associated type), as outlined in the angiographic core lab prot ocol. 
10.1.1. P REPARATION  
Procedural techniques will be in accordance with the institutio n a l  s t a n d a r d  o f  c a r e  f o r  
balloon angioplasty of the superf icial femoral and proximal pop liteal arteries. 
All subjects should receive the appropriate antiplatelet therap y per Table 6. Study 
Medications above ( Section 9.2 ).  
All sites will receive study devices containing a 120cm length delivery catheter to facilitate 
either contralateral or ipsilate ral vascular access, per operat or discretion. 
Ruler Placement: A radiopaque ru ler is placed directly on the s ubjectâ€™s target limb under the 
s t e r i l e  d r a p e s .  T h e  e n d  o f  t h e  r u l e r  s h o u l d  b e  p l a c e d  a t  t h e  t i b i a l  p l a t e a u .  I n  a n y  l a t e r  
assessments, including follow-up duplex and X-Ray evaluations, the process will be repeated 
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 31 of 6Íµ 
to identify the treatment location. All other measurements are referenced back to this 
angiographic measurement.  
Refer to the Instructions for Use (IFU) for a description of th e procedure. 
10.1.2. B ASELINE ANGIOGRAPHIC REQUIREMENTS  
Baseline angiographic measuremen ts of the target lesion (visual  estimate) shall be captured 
to determine eligibility and inc lude, but are not limited to th e following: 
ÂƒTarget Lesion Location (Prox. SF A, Mid SFA, Distal SFA, Prox. P opliteal [P1])
ÂƒBaseline Lesion Length
ÂƒLesion type (Single, Combination or Tandem / De novo or Non-ste nted restenotic
ÂƒReference Vessel Diameter (proximal and distal)
ÂƒCalcification Severity (None, Mild, Moderate or Severe)
ÂƒBaseline Diameter Stenosis (%)
ÂƒNote: The number of subjects wit h total occlusions (100% occlud ed target
lesion at baseline) will be clos ely monitored by [CONTACT_336532] 20% of subjects enrolled in the study. Once this rate ha s been
reached, sites will be appropriately notified by [CONTACT_456].
ÂƒNumber of patent (<50% DS) infra popliteal vessels to the ankle (must have at least
one patent vessel that has not b een revascularized to qualify f or this study)
ÂƒPresence of thrombus
Subjects that are eligible for e nrollment and present with bila teral stenosis (qualifying 
lesions in both limbs) may be en rolled under the following cond itions: 
ÂƒThe more severe stenosis, per op erator discretion, that is inte nded to be treated
with only balloon angioplasty should be considered for enrollme nt.
ÂƒPer operator discretion, the non -target limb lesion can be trea ted by [CONTACT_336533] 14 days prior to
or 30 days after enrollment (Note: If the PI [INVESTIGATOR_336496], it would not
be considered an adverse event a t time of occurrence if treated  after enrollment, but
this should not be less than [ADDRESS_415784] index procedure).
If subjects that are eligible fo r enrollment and present with b ilateral stenosis are 
determined by [CONTACT_978] [INVESTIGATOR_336497], the subject should 
not be enrolled. 
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 32 of 6Íµ 
10.2. P RE-ENROLLMENT BALLOON ANGIOPLASTY  
All consented subjects undergoing balloon angioplasty for possi ble enrollment into this study 
shall receive PTA treatment with  a standard balloon or FDA-appr oved Lutonix drug-coated 
balloon. 
Note: Requirements for pre-dilata tion with a stan dard balloon ( non-drug coated) preceding 
treatment with a DCB should be p erformed in accordance with the  respective IFU. Once the DCB 
is introduced, inflations should be performed according to reco mmendations below for balloon 
angioplasty. Operators should follow these recommendations unle ss patient safety concerns 
present. 
The recommendations for balloon inflation are as follows: 
ÂƒThe operator should select a balloon diameter that can be infla ted to a ratio of 1.1:1
relative to the target lesion proximal RVD.
ÂƒThe length of the balloon should be appropriate for the lesion length. When possible, a
single balloon should be selecte d that extends across the entir e lesion. If a DCB is being
used, then the relevant instruct ions for use should be referenc ed for lesion lengths
requiring multiple balloons.
ÂƒBalloon Inflation: Inflate the ba lloon and maintain inflation a t the specified 1.1:1
diameter for a minimum of 60 seconds total (180 seconds is reco mmended).
Please refer to the Instructions for Use (IFU) for detailed ins tructions regarding Pre-
Enrollment Balloon Angioplasty inflation recommendations.  
10.2.1. P OST-ANGIOPLASTY ANGIOGRAPHIC REQUIREMENTS
Final angiographic eligibility of subjects for study device tre atment will be determined post 
pre-enrollment balloon angioplasty  and include the following ta rget lesion measurements 
(by [CONTACT_13729]): 
ÂƒTarget lesion residual diameter stenosis <30%
ÂƒPresence of dissection(s)
ÂƒPresence of thrombus
In addition, other lesion measurements and balloon details will  be recorded during Pre-
Enrollment Balloon Angioplasty a nd include but are not limited to the following: 
ÂƒTotal number of dissection(s) visualized
ÂƒDissection characteristics (by [CONTACT_13729]) for each dissec tion visualized
Â‹ÂÂ…ÂÂ—Â†Â‹ÂÂ‰Ç¢
oDissection Type (A through F)
oDissection Length
ÂƒBalloon Type (standard or drug-coated), Length, Diameter
ÂƒFor each balloon inflation:
o Inflation Duration(s) at Max Pressure
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 33 of 6Íµ 
oMax Pressure (ATM)
10.3. S TUDY DEVICE TREATMENT  
Subjects that meet all inclusion and angiographic inclusion cri teria, and do not meet any 
exclusion or angiographic exclusion criteria will be deemed eli gible for Study Device Treatment. 
10.3.1. E NROLLMENT (INTENT -TO-TREAT ) 
A subject is defined as an intent-to-treat (ITT) patient and of ficially enrolled in the study 
once the Tack Endovascular System is advanced through the intro ducer sheath.  Subjects in 
whom at least one Tack is not pl aced, will be exited after [ADDRESS_415785] one Tack is placed will be followed for 36 months.  
In addition, the per-protocol (PP) population will be defined a s ITT subjects with evaluable 
data that have met the definition for device success, excluding  subjects with major 
deviations such as: 
ÂƒA major inclusion/exclusion criterion deviation Ç¢Â‘Â”
ÂƒA major procedural deviation
The criteria for deviations meeting the classification of â€œmajo râ€ will be defined before study 
endpoint data is available for statistical analysis. All major deviations will be adjudicated by 
[CONTACT_336534]. 
10.3.2. T REATMENT RECOMMENDATIONS  
The lesion considered for Tack placement is assessed with a min imum of two angiographic 
views, an anterior-posterior vie w and a [ADDRESS_415786] Vascular recommends deplo yment of a Tack to the distal e dge of the target dissection. 
If additional Tack implants are required, the operator should c ontinue proximally to the 
next planned deployment site. A m inimum gap distance of 4.0mm b etween Tacks (end to 
end) is recommended. Overlappi[INVESTIGATOR_336498] .  
Please refer to the Instructions for Use (IFU) for detailed ins tructions regarding 
recommended criteria for Tack En dovascular System placement.  
10.3.3. P OST-STUDY DEVICE TREATMENT MEASUREMENTS  
The following information should be recorded Post-Study Device Treatment: 
ÂƒDevice Success
ÂƒNumber of Device Systems used to  treat subject and associated l ot numbers
ÂƒNumber of Tacks Deployed
oRuler location of each deployed Tack (From distal to proximal t o measure
distance between Tacks)
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 34 of 6Íµ 
oNumber of Tacks deployed to trea t each dissection identified in  Section
10.2.[ADDRESS_415787]-DILATATION OF TREATED LESION (POST-STUDY DEVICE ) 
Post-dilatation of the target le sion is required in order to se at the anchors of the Tack. 
10.4.1. R ECOMMENDATIONS  
After Tack placement, it is reco mmended that post-dilatation of  all deployed Tacks be 
performed using the following criteria. 
ÂƒThe balloon size for po st-dilatation should use the largest bal loon diameter used
during angioplasty prior to Tack placement.
ÂƒPost-Dilatation Duration at Max Pressure: A minimum 120 seconds .
ÂƒPost-dilatation balloon angioplasty should be performed with a new standard
balloon catheter (non-drug coated ) to reduce the risk of contac t with deployed Tacks
while advancing the balloon catheter into place.
Please refer to the Instructions for Use (IFU) for detailed ins tructions regarding post-Tack 
placement balloon angiop lasty recommendations. 
10.4.2. F INAL TREATMENT RESULTS
The following information should be recorded after post-dilatat ion and upon completion of 
index procedure: 
ÂƒDetails for balloon used for post-dilatation:
oType (standard or drug-coated), Length, Diameter
oFor each balloon inflation:
ÂƒInflation Duration(s) at Max Pressure
ÂƒMax Pressure (ATM)
ÂƒFinal residual diameter stenosis of target lesion treated with Tacks
ÂƒBailout stent occurrence (post-study device treatment)
oIf applicable, bailout stent device details will be recorded
ÂƒProcedure time (defined as the t ime of insertion of introducer sheath to the time of
withdrawal of last post-Tack dilatation PTA balloon catheter)
ÂƒAdverse event occurrence
ÂƒProcedural Success
10.5. B AILOUT STENTING OF TARGET LESION (POST-STUDY DEVICE ) 
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 35 of 6Íµ 
The use of a bailout stent may occur in the event of persistent flow-limiting dissection not able 
to be treated with the Tack (or as otherwise required for safet y of the subject). All enrolled 
subjects in whom at least one Ta ck is placed and receive a bail out stent will be followed for the 
duration of the study. 
POST-PROCEDURE /PRE-DISCHARGE
All subjects will be assessed pr ior to discharge (Pre-Discharge ) and shall receive a medical regimen 
for the medications required post-procedure per Table 6  in Section 9.2 . All concomitant 
medications (antiplatelet/antico agulant) shall be captured in t he CRF. 
11.1. R EQUIRED ASSESSMENTS
Assessments required at pre-di scharge include the following: 
ÂƒTarget limb resting ABI Measurement (within [ADDRESS_415788]-index  procedure)
ÂƒAdverse event occurrence
ÂƒStudy medication assessment
All subjects receiving treatment with a Tack should be provided  with the Tack Endovascular 
System Patient Implant Card (PIC). The PIC is designed for the patient to carry along with their 
insurance cards. This PIC is to be completed by [CONTACT_336535](s) including the mode l, lot number and location of the 
implanted Tack(s) and the date o f the index procedure. The card  also provides manufacturing 
information and MRI Compatibility. 
REQUIRED FOLLOW -UP VISITS AND ASSESSMENTS  
All subjects will be required to return for clinic follow-up vi sits as outlined in Table 5  of Section 
8.1 and in the sections below.  
12.1. 30- DAY FOLLOW -UP VISIT (-2 DAYS / +[ADDRESS_415789] -INDEX PROCEDURE ) 
The following assessments are req uired to be performed at the 3 0-day follow-up visit: 
ÂƒRutherford Classification
ÂƒTarget limb resting ABI
ÂƒDuplex ultrasound
ÂƒPeripheral Artery Questionnaire (PAQ)
ÂƒEQ-5D-3L
ÂƒWalking Impairment Questionnaire (WIQ)
ÂƒMajor adverse event (MAE) occurrence
ÂƒAdverse event occurrence
ÂƒReview of concomitant medications (antiplatelets/anticoagulants )
12.2. 6  MONTH FOLLOW -UP VISIT (Â±[ADDRESS_415790] -INDEX PROCEDURE ) 
The following assessments are req uired to be performed at the 6  month follow-up visit: 
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 36 of 6Íµ 
ÂƒRutherford Classification
ÂƒTarget limb resting ABI
ÂƒDuplex ultrasound
ÂƒPeripheral Artery Questionnaire (PAQ)
ÂƒEQ-5D-3L
ÂƒWalking Impairment Questionnaire (WIQ)
ÂƒMajor adverse event (MAE) occurrence
ÂƒAdverse event occurrence
ÂƒReview of concomitant medications (antiplatelets/anticoagulants )
12.3. 12  MONTH FOLLOW -UP VISIT (Â±[ADDRESS_415791] -INDEX PROCEDURE ) 
The following assessments are req uired to be performed at the 1 2 month follow-up visit: 
ÂƒRutherford Classification
ÂƒTarget limb resting ABI
ÂƒDuplex ultrasound
ÂƒX-Ray assessment
ÂƒPeripheral Artery Questionnaire (PAQ)
ÂƒEQ-5D-3L
ÂƒWalking Impairment Questionnaire (WIQ)
ÂƒMajor adverse event (MAE) occurrence
ÂƒAdverse event occurrence
ÂƒReview of concomitant medication s (antiplatelets/anticoagulants )
12.4. 24  MONTH FOLLOW -UP VISIT (Â±[ADDRESS_415792] -INDEX PROCEDURE ) 
The following assessments are req uired to be performed at the 2 4 month follow-up visit: 
ÂƒRutherford Classification
ÂƒTarget limb resting ABI
ÂƒPeripheral Artery Questionnaire (PAQ)
ÂƒEQ-5D-3L
ÂƒWalking Impairment Questionnaire (WIQ)
ÂƒMajor adverse event (MAE) occurrence
ÂƒAdverse event occurrence
ÂƒReview of concomitant medications (antiplatelets/anticoagulants )
12.5. 36  MONTH FOLLOW -UP VISIT (Â±[ADDRESS_415793] -INDEX PROCEDURE ) 
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 37 of 6Íµ 
ÂƒThe following assessments are req uired to be performed at the 3 6 month follow-up
visit: Rutherford Classification
ÂƒTarget limb resting ABI
ÂƒPeripheral Artery Questionnaire (PAQ)
ÂƒEQ-5D-3L
ÂƒWalking Impairment Questionnaire (WIQ)
ÂƒMajor adverse event (MAE) occurrence
ÂƒAdverse event occurrence
12.6. R EVIEW OF CONCOMITANT MEDICATIONS (ANTIPLATELETS /ANTICOAGULANTS )DUPLEX
ULTRASOUND (DUS) A SSESSMENT  
Lower extremity arterial duplex ultrasonography is widely accep ted as a method of 
determining arterial stenosis. Duplex ultrasonography combines spectral Doppler 
Technology in addition to B-mode imaging to allow the visualiza tion of blood flow patterns 
within the arteries and veins. This spectral Doppler also provi des a method to measure the 
velocity of the blood flow at specific locations. 
The peak systolic blood flow velocity within the Tacks as well as the target vessel will be 
taken to determine the peak systolic velocity ratio (PSVR). All  scheduled and unscheduled 
DUS exams shall be reviewed by a n independent core laboratory f or analysis.  
The DUS exam should be performed  on all subjects at the 30-day,  6, and 12 month follow-up 
visits. Duplex ultrasonography and/or angiography should be per formed prior to any 
endovascular intervention during the follow-up period in order to assess the treated vessel 
patency. Operators should have e xperience with DUS and the spec ific methods for calculating 
the blood flow velocities. Operators will be trained on the DUS  protocol provided by [CONTACT_336536]. Each operator is required to submit  a test case DUS exam to the 
core lab prior to performing a ny study-required DUS exams. 
A comprehensive overview for DUS acquisition requirements can b e found in the core 
laboratory manual.  
12.7. X-R AY ASSESSMENT  
An X-Ray assessment will be required at the 12 month follow-up visit to assess Tack integrity 
for all subjects in whom at leas t one Tack was placed during th e index procedure.  
ÂƒAcquire all x-rays as a high resolution image
oExposure < 80 kVp
oMagnification of 1.5 image intensifier/receptor magnification
oAvoid overlying bone and image entire Tacked segment(s)
ÂƒMake certain the radiopaque ruler is placed perpendicular to th e imaging plane, flat
on the patient. The ruler must b e present in all film sequences  to be analyzed. Once
placed, the ruler should not be moved during the entire procedu re.
ÂƒUse multiple acquisition views as defined in the x-ray protocol  established by [CONTACT_336537].
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 38 of 6Íµ 
A comprehensive overview of proc edural requirements for X-Ray a ssessments can be found 
in the core laboratory manual. 
12.8. U NSCHEDULED VISITS  
A subject who presents to the in vestigational site between sche duled study-required follow-up 
visits for a target limb related adverse event or intervention to target limb is considered to have 
an â€œunscheduled visitâ€. Every ef fort should be made to gather d ata from the same clinical 
assessments required at the 12 month follow-up visit, including  angiographic (if Target limb 
revascularization occurs), DUS a nd X-ray imaging (if clinically  indicated or per standard of 
care). At the very least, target  limb resting ABI measurement a nd Rutherford Classification 
should be assessed prior to any intervention to the target limb . In any case, if a Target limb 
intervention occurs, all the dat a from any assessment (clinical  or imaging) performed prior to 
the intervention should be recorded in the Unscheduled Visit eC RF.   
In the event a subject receives an intervention on the target v essel and/or lesion, all associated 
media (angiographic, DUS and X-Ray) shall be performed in accor dance with imaging protocols 
and should be provided to the re spective core labs. If a subjec t presents for target limb 
intervention that does not involve the target vessel/lesion, bu t the imaging performed captures 
the target lesion and Tacked por tion vessel, suc h imaging shoul d be sent to the respective core 
lab. 
12.9. F OLLOW -UP VISIT COMPLIANCE  
As part of the informed consent process, all reasonable efforts  will be made to obtain complete 
data for all subjects according to the follow-up visit schedule . Investigators and research staff 
will be expected to maintain con tinuous and open communication with study subjects 
regarding their participation in this study. 
Three attempts via telephone will be made to contact [CONTACT_1766] w ho do not present for study 
follow-up visits. If after three telephone attempts, the subjec ts cannot be contact[INVESTIGATOR_530], a certified 
letter should be sent by [CONTACT_978] o r designated study coordinator  to the subjectâ€™s last known 
address. If possible, public records should be searched to asce rtain survival status. If efforts to 
reach the subject are unsuccessf ul after three telephone contac ts and a certified letter and there 
is no evidence of subject expi[INVESTIGATOR_51520], the sites will complete a  Protocol Deviation for a Visit Not 
Done. A detailed record of all contact [CONTACT_336538]â€™s file. This 
process should be repeated for every subsequent follow-up visit  and documented accordingly. 
These subjects will not be consi dered lost-to-follow-up (LTFU) and exited from the study until 
the end of the final follow-up visit window, unless it becomes known to the site that the subject 
has expi[INVESTIGATOR_336499].  
12.10. S UBJECT DISCONTINUATION AND REPLACEMENT  
A subject may discontinue parti cipation at any time without pen alty or loss of benefits to which 
the subject is otherwise entitled. In addition, a subject may b e discontinued if in the 
investigatorâ€™s opi[INVESTIGATOR_336500]â€™s best interest. If  a subject prematurely discontinues 
from the study, the reason will be recorded in the eCRF with su pporting documentation.  These 
results will be tabulated by [CONTACT_336539].   
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 39 of 6Íµ 
Subjects who prematurely exit th e study after treatment will ha ve their data maintained and
evaluated up until the time of withdrawal. Subjects who are vol untarily or involuntarily (per PI 
[INVESTIGATOR_9106]) withdrawn cannot re-enter the study. These subjects  will not be replaced. 
RISK/BENEFIT ASSESSMENT  
13.1. R ISKS 
The use of the Tack Endovascular System in percutaneous translu minal balloon angioplasty 
(PTA) may result in anticipated potential risks or complication s similar to other available 
endovascular implant devices (su ch as stents) used in PTA proce dures. Such risks are included 
in the Tack Endovascular System Instructions for Use (IFU) and are listed below: 
ÂƒAccess failure or abrupt closure
ÂƒAllergic / anaphylactoid reactio n to anticoagulant and/or antit hrombotic therapy or
contrast medium
ÂƒAllergic reaction to nitinol
ÂƒAmputation of lower extremity
ÂƒAnemia
ÂƒAngina / coronary ischemia / myocardial infarction
ÂƒArrhythmia
ÂƒArterial occlusion / (re) stenosis / dissection / thrombus
ÂƒArterial spasm
ÂƒArteriovenous fistula
ÂƒBlue toe syndrome
ÂƒClaudication or rest pain, worsened
ÂƒDeath
ÂƒDisseminated intravascular coagulation
ÂƒEdema, peripheral
ÂƒEmbolism
ÂƒEmergent repeat hospi[INVESTIGATOR_336501]
ÂƒFever
ÂƒGangrene
ÂƒGastrointestinal bleed from anti coagulation / antiplatelet medi cation
ÂƒHematoma / hemorrhage
ÂƒHypotension / hypertension
ÂƒInadvertent venipuncture
ÂƒInfection / abscess at insertion site
ÂƒInflammation
ÂƒMulti-organ failure
ÂƒPain
ÂƒPseudoaneurysm
ÂƒRenal insufficiency or failure
ÂƒRespi[INVESTIGATOR_179184]
ÂƒSepticemia / bacteremia (sepsis)
ÂƒTack implant embolization
ÂƒTack implant migration (device moves over time)
ÂƒTack implant occlusion / restenosis
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 40 of 6Íµ 
ÂƒTissue necrosis
ÂƒTrauma to adjacent structures
ÂƒStroke / TIA (hemorrhagic / embolic)
ÂƒVascular complications which may require surgical repair
These risks are present in any e ndovascular treatment procedure  for which the study subjects 
would be indicated because of th eir disease and will be reviewe d with all subjects during the 
informed consent process. 
13.2. P OTENTIAL BENEFITS  
Prior human studies validated that the Tack Endovascular System  can safely and effectively 
appose dissected tissue in subjects with post-PTA dissections, thereby [CONTACT_336540].   
13.3. J USTIFICATION FOR CLINICAL STUDY  
T h e  s a f e t y  a n d  p e r f o r m a n c e  o f  t h e  T a c k  E n d o v a s c u l a r  S y s t e m  has been established through 
extensive design verification and validation testing, including  prior human use, and through a 
detailed risk analysis process per ISO [ZIP_CODE]. The results of no n-clinical and clinical testing have 
demonstrated safety and benefit and therefore, it is anticipate d that the assessment of risk and 
benefit is appropriate for the in tended use of the study device  and the initiation of this study. 
This trial is being conducted in order to collect additional sa fety and effectiveness data on the 
Tack Endovascular System device to support a Premarket Approval  (PMA) application. All efforts 
w i l l  b e  m a d e  t o  m i n i m i z e  t h e  o c c u r r e n c e  o f  r i s k  t o  s t u d y  s u b j e c ts through 
investigator/institution qualification, investigator training o n the safe and proper use of the 
device in accordance with the IFU, investigator/site training o n the protocol, and clearly defining 
subject eligibility requirements (inclusion/exclusion criteria)  and contraindications as described 
in the IFU. 
ADVERSE EVENT REPORTING
The adverse event (AE) reporting  period will begin at the time of enrollment into the study (See 
Section 10.3.1 ) and will continue thro ugh study completion.  
The Principal Investigator [INVESTIGATOR_336502]/EC policy an d in accordance with FDA 
requirements. All Adverse Events  during the safety observation period should be followed until the 
event is resolved or judged to b e chronically stable. Follow-up  information will be submitted to the 
Medical Monitor and/or the Sponsor as it becomes available. 
All adverse events mus t be recorded on the Adverse Event CRF by  [CONTACT_737] (or designee).  
The report should include: sever ity, duration, action taken, tr eatment outcome and relationship of 
the adverse experience to the st udy device, procedure, concomit ant medications, pre-existing 
condition, (i.e., unrelated, related or relationship unknown). 
All events will be made accessible to the Sponsor and/or design ee to review the need for FDA 
regulatory reporting. All AEâ€™s w ill be reviewed for their relat ionship to the study device(s) and/or 
procedure and severity of the event.  
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 41 of 6Íµ 
Severity of adverse events will be classified according to the following criteria: 
Mild:  A mild adverse event is an AE u sually transient in nature and generally not interfering 
with normal activities. 
Moderate:  A moderate adverse event is an AE that is sufficiently discomf orting to interfere 
with normal activities. 
Severe:  A severe adverse event is an AE  that is incapacitation and pre vents normal 
activities. 
The relationship of the AE to th e device or procedure will be c lassified according to the following 
criteria: 
Unrelated:  No relationship to the study device or study procedure. 
Possibly:  Signs or symptoms are the study device or study procedure and the natural 
disease process or other injury/illness.
Definitely:  Clearly related to the study de vice and/or study procedure. Si gns and symptoms 
not related to natural disease process or other injury/illness.  
Unknown:  Unable to determine relationship between study device, study p rocedure, 
natural disease process and/or other injury/illness. 
14.1. A DVERSE EVENTS (AE) 
An adverse event (AE) is any unt oward medical occurrence, unint ended disease or injury, or 
untoward clinical signs (includi ng abnormal laboratory findings ) in subjects, users or other 
persons, whether or not related to the investigational device/p rocedure. 
For purposes of this study, the following events are not consid ered adverse events because they 
are normally expected to occur in conjunction with endovascular  procedures / post-procedure, 
or are associated with customary,  standard care of subjects und ergoing these procedures: 
ÂƒEarly post-operative pain (within [ADDRESS_415794]-index procedure ) at the access site
and/or related to position on procedure table
ÂƒMinor, localized tenderness, swelling, induration, bruising, oo zing, hematoma <5 cm at
vascular access site
ÂƒPost-anesthesia/conscious sedation emesis, nausea, or headache (within [ADDRESS_415795]-
index procedure)
ÂƒChest pain without associated ECG changes
ÂƒHematocrit decrease from baselin e not associated with hemodynam ic changes,
remaining above 30% and not requiring transfusion
ÂƒElectrolyte imbalance without cl inical sequelae following PTA/T ack procedure, even if
requiring correction
ÂƒLow grade temperature increase ( Î¶38Â°C/Î¶101.4Â°F)
ÂƒSinus bradycardia/tachycardia th at does not require treatment o r intervention
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 42 of 6Íµ 
ÂƒSystolic or diastolic blood press ure changes that do not requir e treatment or
intervention
ÂƒAny pre-planned (planned prior to enrollment) surgical/endovasc ular procedures
This listing of events is intended to provide guidance to the i nvestigational sites for purposes of 
adverse event reporting.  The Inv estigator at the investigation al site should utilize his/her own 
clinical judgment in evaluating adverse experiences, and may de cide that the above events 
should be reported as adverse events. 
14.1.1. AE  REPORTING  
All AEs will be evaluated to dete rmine whether th e event furthe r meets the criteria for ADE, 
SAE, MAE, SADE, or UADE and will be subject to the respective r eporting requirements as 
outlined in the sections below. Non-serious and non-device rela ted AEs must be reported to 
the Sponsor in a timely manner and must also be submitted to th e IRB/EC per policy. 
14.2. A DVERSE DEVICE EFFECTS (ADE) 
An adverse device effect is defined as any untoward adverse eve nt related to the use of an 
investigational or unintended response to a medical device.  
Note 1: This definition includes adverse events resulting from insufficient or inadequate 
Instructions for Use, deployment , implantation, installation, o r operation, or any malfunction of 
the investigational medical device. This definition includes an y event resulting from 
insufficiencies or inadequacies in the Instructions for Use or the deployment of the device or 
any event that i s a result of user error (See Section 15 ). 
Note 2: This definition includes any event resulting from use e rror or from intentional misuse of 
the investigational medical device (See Section 15 ). 
A list of events that may be associated with the study device a nd/or the index procedure is 
provided in Section 13.[ADDRESS_415796] be evaluated to de termine whether the event furth er meets criteria for an 
SADE (See Section 14.5 ) and would be subject to respective reporting requirements. No n-
serious, anticipated ADEs must be reported by [CONTACT_737] (or designee) to the Sponsor 
in a timely manner and must also  be submitted to the IRB/EC per  policy. If the event 
occurred as a result of a device event, respective reporting re quirements must be followed 
as outlined in Section 15 .  
14.3. S ERIOUS ADVERSE EVENTS (SAE) 
A serious adverse event (SAE) is  defined an adverse event that:   
Âƒled to death,
Âƒled to a serious deterioration in the health of the subject, th at either resulted in:
Âƒa life-threatening illness or injury, or
Âƒresulted in a permanent impairment of a body structure or a bod y function, or
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 43 of 6Íµ 
Âƒrequired in-patient hospi[INVESTIGATOR_10909], or
Âƒresulted in medical or surgical intervention to prevent life-th reatening illness or injury
or permanent impairment to body structure or a body function, o r,
Âƒled to fetal distress, fetal death or a congenital abnormality or birth defect.
Note: Planned hospi[INVESTIGATOR_272] a pre-existing condition, or a procedure required by [CONTACT_141138], i s not considered a serious adverse 
event.   
14.3.1. SAE  REPORTING  
All SAEs must be evaluated to de termine whether the event furth er meets criteria for an 
SADE (See Section 14.5 ) and would be subject to respective reporting requirements. Al l 
events that meet the c riteria above for SAEs  must be reported b y the Investigator (or 
designee) to the Sponsor within [ADDRESS_415797] 
also be reported to the IRB/EC per policy. 
14.4. M AJOR ADVERSE EVENTS (MAE) 
For the purpose of this study, the definition of major adverse event(s)(MAEs) includes the 
following events that comprise sa fety and observational endpoin ts for this study: 
ÂƒIndex limb amputation (major)
ÂƒClinically-driven target lesion revascularization (TLR)
ÂƒAll-cause death
14.4.1. MAE  REPORTING
All events that meet the criteri a above for an MAE must be repo rted by [CONTACT_737] (or 
designee) to the Sponsor within [ADDRESS_415798] also be reported to the IRB/EC per policy.  
14.5. S ERIOUS ADVERSE DEVICE EFFECTS (SADE)
A serious adverse device effect ( SADE) is defined as an adverse  device effect (ADE) that results 
in any of the consequences characteristics of a serious adverse  event (SAE). 
14.5.1. SADE  REPORTING  
All events that meet the criteri a above for an S ADE must be rep orted by [CONTACT_737] (or 
designee) to the Sponsor within [ADDRESS_415799] 
also be reported to the IRB/EC p er policy. If the event occurre d as a result of a device event, 
respective reporting requirements must be followed as outlined in Section 15 . 
14.6. U NANTICIPATED ADVERSE DEVICE EFFECTS (UADE) 
An Unanticipated Adverse Device Effect (UADE) is any serious ad verse effect on health or safety 
or any life-threatening problem or death caused by, or associat ed with, a device, if that effect, 
problem, or death was not previously identified in nature, seve rity, or degree of incidence in the 
Â‹ÂÂ˜Â‡Â•Â–Â‹Â‰ÂƒÂ–Â‹Â‘ÂÂƒÂÂ’ÂÂƒÂÇ¢Â‘Â”ÂƒÂÂ›  other unanticipated problem associated with a device that rela tes to 
the rights, safety, or welfare of the subjects. 
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 44 of 6Íµ 
14.6.1. UADE  REPORTING
Any event that is suspected of m eeting UADE criteria should be reported in the same 
manner as an SAE or SAD E and must be report ed by [CONTACT_148606] (or designee) to the 
Sponsor within [ADDRESS_415800] also be reported 
to the IRB/EC per policy. All SAEs will be reviewed by [CONTACT_19457] (or designee) to 
determine if UADE criteria is me t, and if so will immediately c onduct an evaluation and 
report the results of the evalua tion to FDA, all reviewing IRBs /ECs, and participating 
investigators within [ADDRESS_415801] deviation, median, minimum and max imum for continuous 
variables and will incl ude the number and percent of observatio ns for categorical variables.   
When the mean is found not to be an appropriate measure of cent ral tendency, alternative 
statistics will be considered (e.g. median).  When the distribu tion of a variable does not support 
the use of parametric statistics , nonparametric approaches or d ata transformations may be 
implemented.  If data transformations are used they will be spe cified in the final clinical report.  
16.2. A NALYSIS GROUPS  
Intent to Treat (ITT) :   A subject is defined as an in tent-to-treat (ITT) patient on ce the subject 
has met all the inclusion and exclusion criteria including angi ographic criteria and the Tack 
Endovascular System is advanced through the introducer sheath.  See Section 10.2.1 â€“ 10.3.1  
for details.    
Per Protocol (PP):   The per-protocol (PP) population is defined as the subset of th e ITT 
population with evaluable data that have met the definition for  Device Success, excluding 
subjects with major protoc ol deviations such as: 
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 45 of 6Íµ 
ÂƒA major inclusion/exclusion criterion violation Ç¢Â‘Â”
ÂƒA major procedural deviation
The criteria for deviations meet ing the classification of â€œmajo râ€ will be defined before study 
endpoint data is available for statistical analysis.   All majo r deviations will be adjudicated by [CONTACT_336541]. 
16.3. E NROLLMENT SAMPLE SIZE 
The maximum sample size required for the primary objectives is 178 subjects meeting the ITT 
definition for primary efficacy that are evaluable for the prim ary patency endpoint measured at 
12 months.   The sample size was increased for 15% attrition ov er [ADDRESS_415802] balloons and drug-coated 
balloons will be calculated. The proportions are the weights in  the formula to calculate the 
performance goal.  The cal culation is described in Section 16.8 Performance Goal.  The 
performance goal for primary eff icacy will be fixed in advance of or prospectively to the 
primary efficacy analysis. There is no Type I error adjustment for this report given that no 
hypotheses will be tested.   
16.5. J USTIFICATION FOR POOLING  
The investigational sites will be tested for differences in the  primary safety and efficacy endpoints 
u s i n g  F i s h e r â€™ s  E x a c t  t e s t  i n  t h e  I T T  s a m p l e .   F o r  t h e  p r i m a r y  e fficacy endpoint, sites will be 
additionally stratified by [CONTACT_336542]. drug-coated balloons to  e v a l u a t e  p o o l i n g .   T h e  F i s h e r â€™ s  
Exact test will be performed twi ce, once for subjects treated w ith drug-coated balloons and once 
for subjects treated with standard balloons.  Investigational s ites with fewer than 10 subjects will 
be combined for this purpose.  If there are any investigational  site effects (i.e., statistically 
s i g n i f i c a n t  r e s u l t s  a t  t w o - s i d e d  p  <  . 1 0 ) ,  a  r a n d o m  c e n t e r  e f f e ct will be included in a logistic 
regression model to assess the primary objective.  If there are  no differences, the data from all 
investigational sites will be pooled for the analyses.   
Additionally, the primary safety  and efficacy endpoints will be  summarized by [CONTACT_336543].  The study was not powered to demons trate the primary efficacy and 
safety endpoints within the subgroups defined by [CONTACT_336544]. 
16.6. H ANDLING OF MISSING DATA 
The primary statistical analysis  will be conducted using the ob served data  with standard 
imputations used when the 12 month DUS determination is missing  but an earlier or later DUS 
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 46 of 6Íµ 
or angiogram are available in th e ITT sample (see Primary Statis tical Analysis in Section 16.8 
for more detail).  
Additionally, a sensitivity analysis to the missing data in the  intent-to-treat sample will be 
conducted.  The sensitivity analysis will include a best case, worst case and tippi[INVESTIGATOR_30350].  The best case analysis will impute successes for the  missing data.  The worst case 
analysis will impute failures for missing data.  The tippi[INVESTIGATOR_336503], by [CONTACT_336545].   The goal of the tippi[INVESTIGATOR_336504].  I f the worst case analysis maintains 
statistical significance, the ti ppi[INVESTIGATOR_336505]. 
16.7. S UMMARY OF BASELINE DEMOGRAPHICS , INDEX PROCEDURE MEASUREMENTS , TACK
ENDOVASCULAR SYSTEM TREATMENT RESULTS , AND SUBJECT COMPLIANCE
Baseline demographics including at a minimum, gender, age and s elected medical history will 
be summarized for patients enro lled in the study. In addition, angiographic characteristics and 
measurements, as well as final treatment results captured durin g each phase of the Index 
Procedure (Baseline, Post-PTA, and Post-Study Device) as outlin ed in Section 10  will also be 
summarized.  
Patient follow-up and compliance with the protocol will be repo rted.  The number and percent 
of patients enrolled, completing study required follow-ups and completing the study will be 
summarized.  The patients who exit the study early will be summ arized along with the reason 
for early study termination. 
16.8. P RIMARY SAFETY OBJECTIVE  
Subjects Included the Analysis:  Subjects who meet the ITT definition as specified in Section 16.2 
and 10.3.1. 
Endpoint:  Freedom from the occurrence of any new-onset major adverse eve nt(s) (MAEs) 
defined as index limb amputation  (above the ankle), CEC adjudic ated clinically-driven target 
lesion revascularization (CD-TLR ), or all-cause death at 30 day s as specified in Section 6.1.   
Hypothesis and Performance Goal :  The VIVA performance goal of 88%19 will be used as the 
performance goal for this endpoint.   
H0:  Freedom from MAE (p MAE) is less than or equal to 88% at 30 days, p MAE Î¶ 88% 
H1:  Freedom from MAE is great er than 88% at 30 days, p MAE > 88% 
Sample Size Rationale :  Using PASS 2012, a one-sample Exac t Test, power = 90%, one-side d 
Type I error controlled at 5.0%,  a performance goal of 88% and an assumed freedom from MAE 
at 30 days in Group 1 of 95%, 1 38 subjects with 30 days of foll ow-up and/or an MAE prior to 30 
days are required for the analysis.  
19Rocha-Singh KJ, Jaff MR, Crabtree TR, Bloch DA, Ansel G on beha lf of VIVA Physicians, Inc.  Performance 
Goals and Endpoint Assessments fo r Clinical Trials of Femoropop liteal Bare Nitinol Stents in Patients with 
Symptomatic Peripheral Arterial Disease.  Catheterization and C ardiovascular Interventions 69: 910 â€“ 919 
(2007).   
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 47 of 6Íµ 
Primary Statistical Analysis : The primary statistical analysis will be conducted in subjects who 
meet the ITT definition and have observed data for the primary safety endpoint.  The primary 
statistical method is a one-sample exact test comparing the pro portion of subjects free from a 
MAE to the performance goal using a one- Â•Â‹Â†Â‡Â†È½Î±Í²Ç¤Í²Í·Ç¤ÂŠÂ‡Â‡ÂšÂƒÂ…Â–Â‘ÂÂ‡ -sided 95% confidence 
interval for the proportion of subjects free from MAE will be c alculated.   
The freedom from MAE proportion w ill be calculated such that th e numerator is the number of 
subjects in whom a MAE did not occur within 30 days of the inde x procedure.  The denominator 
is the number of subjects with 30 days of follow-up plus the nu mber of subjects with an MAE 
prior to 30 days who exited the study early, if any.   
Additional Analysis :  If pooling is not justified per the methods outlined in Section 16.5 , the 
additional analyses specified in that section will be completed .  If there is missing data for the 
ITT subjects, the sensitivity to missing data analysis outlined  in Section 16.6  will be completed.  
Additionally, the primary statistical analysis will be conducte d in the per protocol sample.  
16.9. P RIMARY EFFICACY OBJECTIVE  
Subjects Included the Analysis:  Subjects who meet the ITT definition as specified in Section 16.2 
and 10.3.1.  
Endpoint:  Primary patency defined as free dom from CEC adjudicated clinic ally-driven target 
lesion revascularization (CD-TLR) and freedom from core lab adj udicated duplex ultrasound 
derived binary restenosis at 12 months (defined as PSVR >2.5) a s specified in Section 6.1.    
Hypothesis :  
H0:  Primary patency (p p_pat) is less than or equal to perfo rmance goal (PG) at 12 months, pp_pat Î¶ 
PG 
H1:  Primary patency is greater th an the performance goal at 12 m onths, p p_pat > PG 
Performance Goal :  The performance goal is based  upon the [ADDRESS_415803] Drug-Coated Balloon 
(DCB) 
%(n/N) 
[95% CI]Control PTA 
%(n/N) 
[95% CI] 
Primary Patency 65.2% (172/264) 
[59.4, 70.9] 52.6% (71/135) 
[44.2, 61.0] 
The performance goal for TOBA II is derived from the lower limi t of the 95% confidence 
interval for the Test DCB and Co ntrol PTA in Levant 2 given tha t the expectation is that the Tack 
20 Summary of Safety and Effectiveness Data (SSED) LUTONIXÂ® 035 Dr ug Coated Balloon PTA Catheter  
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 48 of 6Íµ 
device will resolve dissections without negatively impacting pr imary patency at 12 months.  
The primary patency rate is dependent on the type of balloon us ed and therefore the 
performance goal will be calcula ted using the Levant 2 lower 95 % confidence limits and the 
proportion of subjects enrolled and treated with DCB (p DCB) and Control PTA (p PTA) in the TOBA 
II Trial. The following formula will be used: 
PG = p DCB X 59% + p PTA X 44% 
For example, assuming the propor tion of subjects meeting the IT T definition in TOBA II is 60% 
DCB and 40% Control PTA, the cal culated performance goal will b e 0.6*59% + 0.4*44% = 53%.  
The primary efficacy performance goal will be calculated upon c ompletion of the index 
procedure for all enro lled subjects (see Section 16.4 ).  
Sample Size Rationale :  The sample size required to have  data evaluable for the primary  efficacy 
endpoint at [ADDRESS_415804], power = 90%, 
one-sided Type I error controlle d at 2.5%, and setting the maxi mum proportion of subjects 
treated with DCB enrolled at 60% . In this case, the performance  goal for primary patency at 12 
month is 53%.  A current estimat e for primary patency at 12 mon ths in the TOBA European trial 
(POBA use only) is 75%.  Conserv atively, the primary patency fo r DCB + Tack and Control PTA + 
Tack was assumed to be 65% for the purpose of the sample size c alculation.   Using those 
assumptions, [ADDRESS_415805] data evaluable f or the primary efficacy endpoint 
at 12 months.   
The power at N=178 subj ects is provided in Table 8 varying the assumed proportion of 
subjects treated with DCB + Tack.   As can be seen in Table [ADDRESS_415806] 90% power given the proportion of su bjects treated with DCB + Tack is 
60% or less.   
Table 8 - Power for N=178 Subjects Varying the Proportion of Subjects Treated with DCB + Tack 
Meeting the ITT Definition with Data Available to Evaluate the Primary Efficacy Endpoint at 12 months  
Proportion of 
Subjects Meeting ITT 
Definition with Tack 
+  Performance
Goala Assumed Patency at 12M
for TOBA II Power at 
N=178 
DCB Control 
PTA DCB + Tack Control PTA 
+ Tack Pooled 
30% 70% 49% 
65% 65% 65% 99.1% 
40% 60% 50% 98.0% 
50% 50% 52% 92.4% 
60% 40% 53% 90.0% 
aThe performance goal, PG, is calculated as PG = proportion DCB + Tack*59 + proportion control PTA + Tack*44.  
Primary Statistical Analysis : The primary statistical analysis will be conducted in subjects who 
meet the ITT definition and have data evaluable for the primary  efficacy endpoint.  Subjects 
with a missing DUS ultrasound at  12 months and a patent DUS ult rasound at a later visit with no 
intervening clinically driven TLR will be considered patent at 12 months.  In the event an 
angiogram is available within the 12 month visit window, the an giographic core-lab determined 
stenosis using the 50% cutoff will be used instead of the DUS c ore-lab determined stenosis.  The 
primary statistical method is a one-sample exact test comparing  the proportion of subjects with 
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 49 of 6Íµ 
primary patency to the performance goal using a one- Â•Â‹Â†Â‡Â†È½Î±Í²Ç¤Í² 25. The exact two-sided 95% 
confidence interval for the proportion of subjects with primary  patency will be calculated.   
The primary patency proportion will be calculated such that the  numerator is the number of 
subjects who are patent at 12 months with no clinically-driven TLR by [CONTACT_336546] 12 month 
visit window.  The denominator i s the total number of subjects with a core-lab adjudicated DUS 
ultrasound finding of either pat ent or not patent at 12 months,  clinically-driven TLR prior to the 
close of the 12 month visit wind ow, or missing 12 month DUS wit h a patent DUS finding at a 
subsequent visit with no intervening clinically driven TLR.   
Additional Analysis:   If pooling is not justified per the methods outlined in Section 16.[ADDRESS_415807] f or changes from baseline for 
endpoints compared to baseline.  Statistical significance will be defined as two-sided  Ä¡Ä½Ä¡Ä±Ä¯Ä±Ä¶Ä¯Ä¡
Two sided 95% confidence intervals may be calculated for estima tes.  P-values and 95% 
confidence intervals are not intended for the labeling.    
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 50 of 6Íµ 
Safety endpoints will be evaluated in the sample of subjects me eting the ITT definition only.  
Efficacy endpoints will be evalu ated in both the ITT and PP sub jects.   
REGULATORY AND ETHICAL OBLIGATIONS  
As the study Sponsor, Intact Vascular is responsible for the ov erall conduct and quality of the study, 
including the assurance that the study complies with the regula tions and guidance that apply to 
medical devices evaluated under an Investigational Device Exemp tion (IDE) and Good Clinical 
Practice (GCP) guidance (FDA Gui dance and ICH E6). Additionally , Intact Vascular will ensure that 
qualified monitors and designated personnel are monitoring the study and that the Informed 
Consent process is followed per each siteâ€™s local and national requirements. 
17.1. I NSTITUTIONAL REVIEW BOARD (IRB)  / ETHICS COMMITTEE (EC)  APPROVAL
The Principal Investigator [INVESTIGATOR_336506]/EC approval 
f o r  t h i s  s t u d y  p r o t o c o l  a n d  t h e  I n f o r m e d  C o n s e n t  d o c u m e n t s .  T h e  I R B / E C  f o r  e a c h  s p e c i f i c  
institution must review and approve this study protocol, the sp ecific Informed Consent form and 
any written materials for subjects to be used at that site prior to enrollment of the first subject. 
The Sponsor must  also review and approve the final Informed Consent documents p rior to their 
use.  The Sponsor must receive a copy of any IRB/EC corresponde nce as well as the final approval 
letter and the final approved Informed Consent from each IRB/EC . The IRB/EC approval letter 
m u s t  b e  s i g n e d  b y  t h e  I R B / E C  c h a i r  o r  d e s i g n e e ,  i d e n t i f y  t h e  I R B/EC name [CONTACT_3816], the 
clinical study protocol by [CONTACT_263668], and the date the app roval was granted. 
The site investigator is also responsible for initiating and ob taining continuing review of the 
clinical study. Continuing IRB/EC review and approval should no t exceed intervals over one year, 
b u t  m a y  o c c u r  a t  m o r e  f r e q u e n t  i n t e r v a l s  a s  r e q u i r e d  b y  s i t e  s p ecific IRB/EC policies. The 
i n v e s t i g a t o r  m u s t  a l s o  p r o v i d e  t h e  S p o n s o r  w i t h  a l l  c o r r e s p o n d e nce and documentation of 
continued IRB/EC approval of the clinical study. 
17.2. I NFORMED CONSENT  
All sites shall comply with 21 CFR 50, provisions of ICH Good C linical Practices (GCPs), local 
IRB/EC policy and all applicable local regulations for obtainin g Informed Consent. Written, 
informed consent is to be obtain ed for all subjects prior to tr eatment as described in Section 
8.3. 
Informed Consent templates will be provided by [CONTACT_328769] a ll participating clinical sites. 
Changes to this template made by [CONTACT_336547]/EC req uirements must be provided 
to the Sponsor for review and approval prior to being submitted  to the IRB/EC for review and 
approval. Any revisions required by a siteâ€™s IRB/EC should also  be provided to the Sponsor for 
review and approval prior to bei ng submitted to the IRB/EC for final review and approval.  
17.3. P ROTOCOL AMENDMENT AND EMERGENCY DEVIATIONS  
Changes to the research conducted under this protocol will be i mplemented with a formal 
protocol amendment. Amendments t o the protocol may be initiated  by [CONTACT_336548]. In either case, changes to the pro tocol must be approved by [CONTACT_336549]. A protocol 
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 51 of 6Íµ 
amendment cannot be implemented a t the site without first being  signed and acknowledged by 
[CONTACT_16270]/EC. 
Emergency deviations or modifications may be initiated without prior Sponsor or IRB/EC 
approval only in cases when the deviation is necessary to elimi nate an immediate potential 
hazard to a subject. Emergency deviations or modifications impl emented to protect the life or 
physical well-being of a subject  must be reported to the Sponso r and site specific IRB/EC 
within [ADDRESS_415808]â€™s medical 
records will be limited to author ized personnel of the Sponsor,  their designated monitors, 
clinical site study staff and authorized regulatory authorities  as required by [CONTACT_1201]/EC and/or 
local or national agencies. Any data that may be published in a bstracts or scientific journals 
and/or presented at medical meet ings will reference a unique su bject code and will not reveal 
the subjectâ€™s identity.  The Spo nsor and their representatives will make every reasonable effort 
to protect the confidentiality of the subjects participating in  the study. 
All U.S. clinical study sites must comply with the provisions o f the Health Insurance Portability 
and Accountability Act (HIPAA) and in accordance with all appli cable federal, local and 
institutional requirements.  
CLINICAL STUDY CONDUCT  
18.1. P RINCIPAL INVESTIGATOR AND SITE QUALIFICATION  
All Principal Investigatorâ€™s (PI) and investigational sites wil l be selected by [CONTACT_336550] [INVESTIGATOR_336507]. All selected PIâ€™ s will be responsible for complying 
with all study-related and regul atory requirements and will be ultimately responsible for 
overseeing the conduct of the study at their respective investi gational sites, per the Investigator 
Agreement.  
All selected PIâ€™s will have the required training and expertise  in performing peripheral vascular 
interventional procedures in a clinical research setting. The i nvestigational sites where the 
study procedures and assessments are to be performed must have the adequate volume of the 
target subject population, experienced staff, as well as the ap propriate facilities and equipment 
to meet the requirements of the s tudy protocol and the expected  enrollment time frames. 
All PIâ€™s and research staff must be willing to undergo all stud y and device-related training and 
participate and assist  with monitoring, audits and inspections initiated by [CONTACT_336551]/or regulatory authorities.  
18.2. P RINCIPAL INVESTIGATOR AND SITE TRAINING  
Training of the Investigators and clinical study staff is the r esponsibility of the Sponsor and 
their designee.  Investigators and study staff will undergo sit e initiation visit training on the use 
of the study device, the study p rotocol, eligibi lity criteria, and device accountability prior to 
participating in the study. Training will also include, but is not limited to, instructions on timely 
and accurate eCRF completion, safety reporting timelines, as we ll as procedures for acquiring 
study related images and associated timelines for submission to  appropriate core laboratory. 
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 52 of 6Íµ 
All training of the Investigators and research staff must be do cumented on the training log 
before performing any study-related function. 
18.3. C LINICAL MONITORING  
Intact Vascular will designate q ualified clinical monitor(s) an d oversee the conduct of this 
study.  The clinical monitors will evaluate compliance with the  protocol, Good Clinical Practices 
(FDA Guidance and ICH E6), any specific recommendations made by  [CONTACT_779]â€™s IRB/EC and the 
signed Investigator and Study Agreements.   
The clinical monitor will conduct periodic monitoring visits to  verify that the eCRFs are in 
agreement with the source docume ntation and other records, that  the rights and well-being of 
the subjects, and that the trial  is being conducted in accordan ce with the approved 
protocol/amendments and GCPs. Pe riodic phone contacts will also  be conducted to ensure that 
the protocol is being followed an d to assist the site with quer ies that may arise.  
For record verification purposes during site monitoring visits,  the clinical monitor and/or 
authorized Sponsor representative will be provided access to ho spi[INVESTIGATOR_1097], original 
laboratory data, and other recor ds and data as they relate to t he study and as agreed to with the 
Investigator prior to the initiation of the trial.  The Investi gator will also make available to the 
clinical monitor all regulatory documents, all completed eCRFs,  informed consent documents, 
source documentation and other r elevant records for all enrolle d subjects at th e site.  It is 
important that the Investigator and other relevant site personn el are available for consultation 
with the clinical monitors during the monitoring visits and tha t sufficient time is devoted at the 
site to the monitoring process.  
If the Sponsor and/or their authorized representative become aw are that an Investigator is not 
complying with the study protoco l, the Investigator Agreement, the Declaration of Helsinki, 
GCPs, applicable privacy standar ds, or any condition of the stu dy imposed by [CONTACT_3433] e IRB/EC, the 
Sponsor or their authorized repr esentative may immediately secu re compliance, discontinue 
further shipments of the study devices and/or seize unused devi ces on-site.  An inability to 
secure compliance and/or to complete an investigation into the factors that are inhibiting 
compliance may result in the Investigatorâ€™s termination from th e study by [CONTACT_1034].   
Study close-out visits will be conducted after the final follow -up visit is completed at each site.  
Following the resolution of any outstanding data discrepancies and adverse events, the 
remaining study devices will be the collected and returned to t he Sponsor.  A final study report 
will be generated and submitted to the Investigator and the app ropriate study oversight 
authorities.  Study document retention requirements will be rev iewed with each site during the 
close-out visit. 
18.4. D EVICE ACCOUNTABILITY  
All study devices will be provided to the Investigator by [CONTACT_941] S ponsor after being tested, released 
and shipped according to appropriate standards. The investigato r and/or designee is 
responsible for the secure storage of and controlled access to the study devices and 
accountability. The study device shall not be dispensed to any person who is not a consented 
study subject under this protocol. 
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 53 of 6Íµ 
18.5. I NVESTIGATOR REPORTS  
All investigators will be responsible for preparing and submitt ing the following complete, 
accurate, and timely reports.  
To the sponsor and the IRB/EC: 
ÂƒAny unanticipated adverse device effect occurring during an inv estigation as soon as
possible but no later than [ADDRESS_415809].
ÂƒAssist sponsor in generating Pro gress reports on the investigat ion at regular intervals,
but in no event less often than yearly. If there is a study mon itor, a copy of the report
will also be sent to the monitor.
ÂƒAny deviation from the investigational plan made to protect the  life or physical well-
being of a subject in an emergency, as soon as possible but no later than 5 working days
after the emergency occurs. Exce pt in emergency situations, a p rotocol deviation
Â”Â‡Â“Â—Â‹Â”Â‡Â•Â’Â”Â‹Â‘Â”Â•Â’Â‘ÂÂ•Â‘Â”ÂƒÂ’Â’Â”Â‘Â˜ÂƒÂÇ¢ÂƒÂÂ†Â‹ÂˆÂ–ÂŠ e deviation may affect the scientific soundness
of the plan or the rights, safety, or welfare of subjects, prio r FDA and IRB/EC approval
are required.
ÂƒAny use of the device without ob taining informed consent, must be reported within 5
working days after such use.
ÂƒAssist sponsor in generating a f inal report within 3 months fol lowing termination or
completion of the investigation or an individual investigatorâ€™s  part of the investigation.
ÂƒAny further information requeste d by [CONTACT_336552]/EC about an y aspect of the
investigation.
To the Sponsor: 
ÂƒWithdrawal of IRB/EC approval of the investigatorâ€™s part of an investigation. (Due
within 5 working days of such action). If the Investigatorâ€™s IR B/EC withdraws their
approval to conduct this study f or any reason, the Investigator  must notify the Sponsor
as soon as possible, but in no ev ent later than five working da ys after the withdrawal of
the approval.
In addition, the Investigator is responsible for the reporting of all clinical and device events per 
the timelines specified in Section 14  and Section 15 .  
18.6. D ATA MANAGEMENT  
Standardized electronic Case Report Forms (eCRF) will be used t o collect complete and 
accurate records of the clinical data required by [CONTACT_336553] (GCP) principles.  The Investigator and/or study staf f under his/her direction is 
responsible for accurately recording the clinical data for this  study within five (5) days after 
each visit. 
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 54 of 6Íµ 
18.7. S AFETY MONITORING  
18.7.1. D ATA SAFETY MONITORING BOARD (DSMB)
To meet the ethical responsibilities and standards for research  subjects, an independent 
board of multi-disciplinary physicians and subject matter exper ts shall serve as the Data 
Safety and Monitoring Board (DSMB) for the study.  In order to enhance objectivity and 
reduce the potential for bias, t he DSMB shall be independent of  the Sponsor as well as the 
investigational sites/ investigators.  
The DSMB shall serve as an independent body conducting a review  and oversight of all key 
safety events to monitor the rate of occurrence (both site repo rted and CEC adjudicated 
events) as part of their mission  to protect the rights and safe ty of research subjects. The 
DSMB will define the types of events that may require real time  reporting and the format 
and frequency of interim data re views for aggregate event rates . The DSMB will conduct 
systematic interim safety reviews at pre-specified intervals as  outlined in the DSMB charter.  
The committee will be responsibl e for making any recommendation s to the Sponsor it 
deems necessary to protect subjects enrolled in the trial. 
At the close of each meeting, del iberation will oc cur and each DSMB member will vote in 
favor of continuation of the study as designed, or modification  of the study to protect the 
welfare of subjects enrolled int o the study. The result of this  vote will be recorded in the 
meeting minutes. A summary of th e meeting output and voting dec ision will be prepared by 
[CONTACT_336554] b e distributed to all participat ing clinical sites for IRB/EC 
continuing review.  
The methodology for performing these responsibilities shall be developed and outlined in 
the DSMB Charter.  
18.7.2. C LINICAL EVENTS COMMITTEE (CEC) 
An independent Clinical Events Committee consisting of a team o f clinical experts with 
experience in the conduct of cli nical trials shall be formed to  review clinical events reported 
by [CONTACT_473], or at the r equest of the Sp onsor to deter mine if they meet the pre-
specified endpoint definitions. The CEC may also be called upon  to review relevant Serious 
Adverse Events to make an assess ment of relationship to study d evice and/or study 
procedure. The CECâ€™s determinati on of whether a clinical event meets the study defined 
endpoint will be considered the primary determination for the p urpose of reporting study 
results with the exception of endpoints derived from Core Labor atory analysis. 
Operational provisions shall be e stablished to minimize potenti al bias (i.e., the physicians 
serving on the CEC shall be blinded to the clinical site to the  extent possible during adverse 
event review and adjudication). The methodology for performing these responsibilities will 
be outlined in the CEC Charter. The CEC will define the minimum  required information 
necessary to facilitate their rev iew of an event. This may incl ude information from original 
source documentation and imaging media. 
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 55 of 6Íµ 
18.8. M EDICAL MONITORING  
The sponsor will be responsible for identifying a Medical Monit or who possesses the 
appropriate expertise and medica l knowledge to oversee all adve rse events reported during the 
study. All adverse event reports will be directed to the Sponso r as well as the Medical Monitor. 
The Medical Monitor will be resp onsible for the first-line and timely review of all adverse 
events in order to identify seriousness, severity, and causalit y and expectedness (anticipated vs. 
unanticipated) of the event to the study device and/or study pr ocedure. The Medical Monitor 
will also have responsibilities including but not limited to: 
ÂƒReviewing all AEs for UADE potential and notifying the Sponsor of the need for
regulatory reporting
ÂƒDetermining the need for additional information or supporting d ocumentation from the
site regarding an adverse event to facilitate complete assessme nt
ÂƒMay help determine if an adverse event meets the criteria for  DSMB/CEC review and
adjudication, as outlined in the charter
ÂƒProviding thorough review and assistance (if needed) for genera ting documents (i.e.,
subject event narratives) subjec t to CEC review and adjudicatio n.
ÂƒProviding answers to the sites, IRBs/ECs, and/or Sponsor to que stions requiring
medical expert[INVESTIGATOR_336570] t o the protocol (i.e., subject e ligibility) or any other
medical aspect of the study
ÂƒReviewing protocol and procedural deviations
ÂƒIdentifying potential need for  an amendment to the protocol
ÂƒProvide a review of safety infor mation included in regulatory r eporting
The Medical Monitor will review all adverse events throughout t he duration of the study until 
study completion. 
18.9. C ENTRAL CORE LABORATORIES  
To ensure that the clinical data and images are analyzed in a c ontrolled, non-biased manner and 
that the results are analyzed using a standardized process, all  angiograms, duplex ultrasound 
studies and x-ray obtained during this study will be submitted to a respective central core lab 
for analysis. 
The core labs will be responsible  for analyzing the angiograms,  duplex ultrasound and x-ray 
images according to the study eligibility criteria, the study e ndpoints and requirement 
measurements according to this s tudy protocol. Feedback will be  provided to the sites and 
Sponsor regarding the quality of  the tracings and images and fo r providing a written summary 
report of all angiogram, duplex ultrasound and X-ray results to  the study Sponsor. 
18.10. R ECORD RETENTION
The Principal Investigator [INVESTIGATOR_336508] f ollowing accurate, complete, and 
current records relating to his/her participation in this inves tigational study:  
ÂƒCorrespondence with another investigator, an IRB/EC, the Sponso r, a monitor, o Â”	Ç¢
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 56 of 6Íµ 
ÂƒRecords of receipt, use or dispo sition of a device that relate to:
oThe type and quantity of the device, dates of receipt, and batc h numbers or code
marks
oNames of all persons who received , used, or disposed of each de vice
oThe number of units of the device returned to the sponsor, repa ired, or
Â‘Â–ÂŠÂ‡Â”Â™Â‹Â•Â‡Â†Â‹Â•Â’Â‘Â•Â‡Â†Â‘ÂˆÇ¡ÂƒÂÂ†Â–ÂŠÂ‡Â”Â‡ÂƒÂ•Â‘ÂÈ‹Â•ÈŒÂ–ÂŠÂ‡Â”Â‡ÂˆÂ‘Â”Â‡Ç¢
ÂƒRecords of each subjectâ€™s case h istory and exposure to the devi ce, including:
oDocuments evidencing informed consent and, for any use of a dev ice without
informed consent, any written concurrence of a licensed physici an and a brief
description of the circumstances justifying the failure to obta in informed
consent
oAll relevant observations, inclu ding records concerning adverse  device effects
(whether anticipated or not), information and data on the condi tion of each
subject upon entering, and during the course of, the investigat ion, including
information about relevant previous medical history and the res ults of all
Â†Â‹ÂƒÂ‰ÂÂ‘Â•Â–Â‹Â…Â–Â‡Â•Â–Â•Ç¢
oA record of the exposure of each subject to the investigational  device, including
the date and time of each us e, and any other therapy.
ÂƒThe protocol, with documents sho wing the dates of and reasons f or each deviation from
Â–ÂŠÂ‡Â’Â”Â‘Â–Â‘Â…Â‘ÂÇ¢ÂƒÂÂ†
ÂƒAny other records that FDA requires to be maintained by [CONTACT_336555] a category of investigations or a particular in vestigation.
In addition, all Principal Inves tigators and Sub-Investigators (Sub-I) shall disclose to the 
sponsor sufficient and accurate financial information to allow the sponsor to submit 
certification or disclosure of financial interests under 21 CFR  54. All PI(s) and Sub-I(s) shall 
update the information if any relevant changes occur during the  course of the investigation and 
for one year following completion of the study. 
The Sponsor, Core Laboratories a nd clinical sites will maintain  the study records until two (2) 
years after the last marketing a pplication and until there are no pending or contemplated 
marketing applications or at lea st two (2) years have elapsed s ince formal discontinuation of 
clinical development of investigational product. These records may be retained for a longer 
period of time if required by [CONTACT_272040].  The Sponsor will notify each site 
regarding the regulatory requirements for record retention duri ng the study close-out visit. 
18.11. A UDITS /INSPECTIONS  
In accordance with GCP requirements, the Sponsor and/or Designe e may request access to all 
study records, including source documents, for inspection and d uplication.  In the event that an 
Investigator is contact[CONTACT_336556] r elation to this study, the 
Investigator will notify the Sponsor as soon as possible.   
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 57 of 6Íµ 
The Investigator and/or designee s must be available to respond to reasonable requests by 
[CONTACT_336557], CRO and regu latory agency representatives d uring the monitoring and 
inspection process.  The Investi gator must provide the Sponsor with copi[INVESTIGATOR_336509] (i.e. Inspection Observations) or 
their qualification as an Invest igator in clinical studies cond ucted by [CONTACT_1034]. The Sponsor 
will provide any needed assistanc e to the clinical site for reg ulatory audits, if any.   
18.12. S TUDY TERMINATION (STOPPI[INVESTIGATOR_16442] ) 
The Sponsor, IRBs/ECs, or regulatory authorities may terminate the study if the safety and well-
being of study subjects is in jeopardy. If the Investigator ter minates the study at his/her site 
without prior approval by [CONTACT_1034], all details must be prov ided promptly to the Sponsor 
and IRB/EC. 
The Sponsor reserves the right to terminate or reevaluate a sit e for continued participation in the 
study for any of the following reasons: 
ÂƒUnsatisfactory enrollment with respect to eligibility criteria
ÂƒFailure to obtain Informed Consent
ÂƒFailure to report Serious Advers e Events within 2 business days  of knowledge
ÂƒLoss of or unaccounta ble device inventory
ÂƒRepeated protocol violat ions or safety concerns
ÂƒRepeated failure to complete Case Report Forms (or inaccurate/i ncomplete eCRF
completion)
ÂƒFailure to enroll an adequate number of subjects
ÂƒThe potential benefits are unlikely to outweigh the risks (Futi lity)
If the study is terminated by [CONTACT_1034], the investigator(s) will be promptly informed, who 
must then promptly inform the IRB/EC. If the IRB/EC terminates the study, the Investigator will 
promptly notify the Sponsor providing an explanation. 
18.13. C OVERAGE OF SUBJECT EXPENSES  
The treated subjects will not be compensated for their time dur ing the trial.  The Sponsor may 
provide reimbursement for reason able out-of-pocket costs to the  subject associated with travel, 
parking, or other expenses assoc iated strictly with completing the protocol requirements of this 
study that would not normally be covered under routine medical coverage for the subjectâ€™s 
underlying medical condition. This will be provided on a case-b y-case basis and will require 
Sponsor (and/or Designee) approval. 
18.14. C LINICAL STUDY REPORTS  
All information and data generat ed in association with the stud y will be held in strict confidence 
and remains the sole property of  the Sponsor.  The Investigator  agrees to use this information 
for the sole purpose of completing the study and for no other p urpose without prior approval of 
the Sponsor.   
All progress reports will be generated and submitted to FDA by [CONTACT_336558].  If requested, all participatin g Investigators and clinical sites 
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 58 of 6Íµ 
should provide assistance to the Sponsor regarding the data and  any other pertinent 
information to be included in the study reports. All progress r eports submitted to FDA will be 
summarized by [CONTACT_336559]/ EC review, which shall include 
all relevant feedback and/or approval provided by [CONTACT_8415]. 
Upon receipt of the final study data and the final reports from  each center, the Sponsor will 
complete a final study report.  Copi[INVESTIGATOR_336510]. 
18.15. P UBLICATION POLICIES  
At the conclusion of the study, a multi-center manuscript led b y the national study Principal 
Investigator [INVESTIGATOR_336511] a 
reputable scientific journal. The publication of the principal results from any single center 
experience within the trial is not allowed until the preparatio n and publication of the multi-
center results as indicated in the Clinical Trial Agreement. Ex ceptions to this rule require the 
prior approval of National PI [CONTACT_1629] d Intact Vascular. For the purp oses of timely abstract 
presentation and publication, se condary publications will be de legated to the appropriate 
principal authors, and final analyses and manuscript review for  all multi-center data and/or 
single-center experience reports  will require review from Intac t Vascular. 
This study will be registered with clinicaltrials.gov. 
18.16. M EDICARE STUDY CRITERIA  
Access to clinical study data provides opportunities to conduct  further research that can help 
advance medical science or improve patient care. This helps ens ure the data provided by 
[CONTACT_336560] t o maximum effect in the creatio n of knowledge and 
understanding. To this end, the study's results information on all pre-specified outcomes, 
including negative outcomes, will be submitted to ClinicalTrial s.gov not later than one year 
after the study completion date, where the completion date is d efined as the date that the final 
subject was examined or received  an intervention for purposes o f data collection for the 
primary outcome measure. Results submission could be delayed if  an extension is granted to 
Â–ÂŠÂ‡Â”Â‡Â•Â—ÂÂ–Â•Â•Â—Â„ÂÂ‹Â•Â•Â‹Â‘ÂÂ†Â‡ÂƒÂ†ÂÂ‹ÂÂ‡Ç¢ÂŠÂ‘Â™Â‡Â˜Â‡Â”Ç¡Â–ÂŠÂ‡Â”Â‡ÂÂ‡ÂƒÂ•Â‡Â‘ÂˆÂƒÂÂÂ”Â‡ Â•Â—ÂÂ–Â•Â‘ÂÂ’Â”Â‡ -specified outcomes 
will be hastened if the study is terminated early. 
It is not anticipated the device under investigation will treat  a Medicare population 
different than the demographics f ound the investigators' genera l population for this same 
condition including populations eligible for Medicare due to ag e (e.g., 65 years or older), 
disability, or other e ligibility status. Low er extremity periph eral artery disease remains one 
of the most unrecognized manifes tations of systemic arterioscle rosis estimated to affect 
between 3% and 7% of the populati on and up to one in five patie nts above the age of 75.1 
While the overall prevalence of PAD ranges from 3% to 10%, PAD affects 12% to 20% of 
Americans aged 65 years and older.21,22 Because the prevalence of PA D increases with age, the 
results of this study are expected to be generalizable to the M edicare eligible population 
primarily due to program eligibi lity due to age (E.g., 65 years  or older).  
21Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society consensu s for the management of peripheral arterial disease 
(TASC II). J Vasc Surg. Í´Í²Í²Í¹Ç¢Í¶Í·Ç£Í· -S67.  
22 Becker GJ, McClenny TE, Kovacs ME, et al. The importance of inc reasing public and physician awareness of peripheral 
ÂƒÂ”Â–Â‡Â”Â‹ÂƒÂÂ†Â‹Â•Â‡ÂƒÂ•Â‡Ç¤
ÂƒÂ•Â…ÂÂ–Â‡Â”Â˜ÂƒÂ†Â‹Â‘ÂÇ¤Í´Í²Í²Í´Ç¢Í³ÍµÇ£Í¹ -11.
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 59 of 6Íµ 
STUDY DEFINITIONS  
Term Definition 
Activated Clotting Time 
(ACT)  Clotting test for high-dose heparin anticoagulation. 
Acute Renal Failure Acute post-operative renal insufficiency resulting in one or mo re of the 
following  (a) increase of > 1.0 m g/dl in serum creatinine from  most recent 
prior measured level, and curren t measured absolute value is > 2.5 ÂÂ‰È€Â†ÂÇ¢È‹Â„ÈŒ
a new requirement for dialysis. 
Adverse Device Effect (ADE) An adverse device effect is defined as any untoward adverse eve nt related to 
the use of an investigational or unintended response to a medic al device.   
ÂƒNote 1: This definition includes adverse events resulting from insufficient
or inadequate Instructions for U se, deployment, implantation, i nstallation, 
or operation, or any malfunction  of the investigational medical  device. This 
definition includes any event resulting from insufficiencies or  inadequacies 
in the Instructions for Use or the deployment of the device or any event 
that is a result of user error (See Section 15 ). 
ÂƒNote 2: This definition includes any event resulting from use e rror or from
intentional misuse of the investigational medical device (See Section 15 ). 
Adverse Event (AE) An adverse event (AE) is any untoward medical occurrence, unint ended 
disease or injury, or untoward c linical signs (including abnorm al laboratory 
findings) in subjects, users or other persons, whether or not r elated to the 
investigational device/procedure. 
Allergic Reaction An allergic reaction characterize d by [CONTACT_932], nausea, vomiting, u pper respi[INVESTIGATOR_137857], urticarial , shortness-of-breath,  vasovagal reaction , or general 
collapse (anaphylaxis). 
Ankle / Brachial Index 
(ABI) The ratio of systolic blood pressure measured at the ankle to s ystolic blood 
pressure measured at the brachia l artery. The ABI is calculated  by [CONTACT_336561] [the higher of the dorsalis pedis (DP) or poster ior tibial (PT) 
artery] by [CONTACT_336562] (the higher of two ar m pressures). 
Resting ABI is performed after a patient has been resting supin e for a 
minimum of 10 minutes. 
Bailout Stenting The use of a bailout stent may o ccur in the event of persistent  flow-limiting 
dissection not able to be treate d with the Tack (or as otherwis e required for 
safety of the subject). 
Balloon Angioplasty A catheter containing an inflata ble balloon (standard or drug-c oated) is 
advanced through a narrowed or o ccluded portion of an artery an d inflated in 
order to open the artery and res tore blood flow. Also referred to as â€œPTAâ€ 
(percutaneous transluminal angioplasty). 
Binary Restenosis Greater than 50% restenosis in t he treated segment as determine d by [CONTACT_336563] 
Â—ÂÂ–Â”ÂƒÂ•Â‘Â—ÂÂ†Â†Â‡Â”Â‹Â˜Â‡Â†Â’Â‡ÂƒÂÂ•Â›Â•Â–Â‘ÂÂ‹Â… Â˜Â‡ÂÂ‘Â…Â‹Â–Â›Â”ÂƒÂ–Â‹Â‘È‹ÈŒÂ‘ÂˆÎ·Í´Ç¤Í·Ç£ Í³Ç¤ 
De Novo Lesion A lesion in the artery that has not been previously treated. 
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 60 of 6Íµ 
Device Deficiency Inadequacy of a medical device r elated to its identity, quality , durability, 
reliability, safety or performan ce, such as malfunction, misuse  or user error 
and inadequate labeling. 
Device Malfunction A malfunction of a device to perform in accordance with its int ended purpose 
when used in accordance with the Instructions for Use. 
Device Success Successful deployment of the Tack(s) at the intended target sit e(s) and 
successful withdrawal of the deli very catheter from the introdu cer sheath. If 
the study device is introduced but the subject does not receive  a Tack due to 
user error and not a device malfunction, this device will not b e included in the 
device success assessment. 
Dissection Disruption of an arterial wall re sulting in separation of the i ntimal layer. May 
or may not be flow limiting. 
Dissection Types (National Heart, Lung and Blood Institute â€“ NHLBI) 
Type A  Small radiolucent area within the lumen of the vessel disappea ring with the 
passage of the contrast material. 
Type B  Appearance of contrast medium parallel to the lumen of the ves sel 
disappearing within a few cardiac cycles. 
Type C  Dissection protruding outside the lumen of the vessel persisti ng after passage 
of the contrast material. 
Type D  Spi[INVESTIGATOR_205349]-off of the contrast 
material in the antegrade flow. 
Type E  Persistent luminal fi lling defect with delayed run-off of the contrast material 
in the distal lumen. 
Type F  Filling defect accompanied by [CONTACT_336564]. 
Drug-Coated Balloon 
(DCB)  FDA-approved Lutonix drug-coated balloon catheter used for perc utaneous 
transluminal (balloon) angioplasty.  
Duplex Ultrasound 
(DUS)  A form of medical ultrasonography that includes the following elements on 
the same screen (â€œduplexâ€) to fac ilitate interpretation  1) B-m ode, pulsed 
Doppler display to visualize the  structure within a vessel and 2) Color-Doppler 
display to visualize the blood flow and hemodynamics within a v essel. 
Index Procedure The interventional procedure during which treatment with the St udy Device 
occurs. 
Intent-to-treat (ITT) 
subjects A subject is defined as an intent-to-treat (ITT) patient and of ficially enrolled in 
the study once the Tack Endovascular System is advanced through  the 
introducer sheath. 
Luminal Patency Restenosis <50% as determined by [CONTACT_336565]. 
Major Adverse Event 
(MAE) Index limb amputation (above the ankle), Clinically-driven targ et lesion 
revascularization, or All-cause death 
Myocardial Infarction (MI) Q wave MI (QWMI): requires one  of the following criteria:  
ÈˆÂŠÂ‡Â•Â–Â’ÂƒÂ‹ÂÂ‘Â”Â‘Â–ÂŠÂ‡Â”ÂƒÂ…Â—Â–Â‡Â•Â›ÂÂ’Â–Â‘ÂÂ•Â…Â‘ÂÂ•Â‹Â•Â–Â‡ÂÂ–Â™Â‹Â–ÂŠÂÂ›Â‘Â…ÂƒÂ”Â†Â‹ÂƒÂ Â‹Â•Â…ÂŠÂ‡ÂÂ‹Âƒ
and new pathological Q waves in two or more contiguous ECG lead s 
ÈˆÂ‡Â™Â’ÂƒÂ–ÂŠÂ‘ÂÂ‘Â‰Â‹Â…Â™ÂƒÂ˜Â‡Â•Â‹ÂÂ–Â™Â‘Â‘Â”ÂÂ‘Â”Â‡Â…Â‘ÂÂ–Â‹Â‰Â—Â‘Â—Â•
ÂÂ‡ÂƒÂ†Â•ÂƒÂÂ† Â‡ÂÂ‡Â˜ÂƒÂ–Â‹Â‘Â
of cardiac enzymes above normal.  
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 61 of 6Íµ 
Non-Q Wave MI (NQWMI): defined a s either: elevated CK = 2X the laboratory 
upper limit of normal with the p resence of an elevated CK-MB (a ny amount 
above the laboratory upper limit  of normal) in the absence of n ew pathological 
Q waves or  elevated CK-MB = 3X t he laboratory upper limit of n ormal in the 
absence of new pathological Q waves.   
Peak Systolic Velocity 
Ratio (PSVR) A measurement (using Duplex Ultrasonography) of peak velocity o f blood 
(cm/sec) within a lesion or stented vessel segment that is divi ded by [CONTACT_336566] (cm/sec) proximal to the lesion of stented se gment.  
Per-protocol (PP) 
subjects The per-protocol (PP) population is defined as ITT subjects wit h evaluable 
data that have met the definitio n for device success, excluding  subjects with 
major protocol deviations such as: 
ÂƒÂÂƒÂŒÂ‘Â”Â‹ÂÂ…ÂÂ—Â•Â‹Â‘ÂÈ€Â‡ÂšÂ…ÂÂ—Â•Â‹Â‘ÂÂ…Â”Â‹Â–Â‡Â”Â‹Â‘ÂÂ˜Â‹Â‘ÂÂƒÂ–Â‹Â‘ÂÇ¢Â‘Â”
ÂƒA major procedural deviation
The criteria for deviations meeting the classification of â€œmajo râ€ will be defined 
before study endpoint data is av ailable for statistical analysi s. All major 
deviations will be adjudicated by [CONTACT_336567]. 
Primary Efficacy 
Endpoint Primary patency defined as freedom from CEC adjudicated clinica lly-driven 
target lesion revascularization (CD-TLR) and freedom from core lab 
adjudicated duplex ultrasound de rived binary restenosis at 12 m onths 
(defined as PSVR >2.5) 
Primary Safety Endpoint Freedom from the occurrence of an y new-onset major adverse even t(s) 
(MAEs) defined as index limb amp utation (above the ankle), CEC adjudicated 
clinically-driven target lesion revascularization (CD-TLR), or all-cause death at 
30 days. 
Procedure Start/End 
Time Start: The time of insertion of introducer sheath              
End: The time of withdrawal of last post-Tack PTA balloon cathe ter 
Procedural Success Demonstrated vessel patency (<30% residual DS, by [CONTACT_336568]) without 
the use of a bailout stent or th e occurrence of MAE upon comple tion of the 
index procedure. 
Renal Insufficiency ÂÂ‹ÂÂ…Â”Â‡ÂƒÂ•Â‡Â‹ÂÂ•Â‡Â”Â—ÂÂ…Â”Â‡ÂƒÂ–Â‹ÂÂ‹ÂÂ‡Â‘ÂˆÎ·Í³Ç¤Í²ÂÂ‰È€Â†Â‘Â˜Â‡Â”Â’Â”Â‡Â˜Â‹Â‘Â—Â•Â˜Âƒ ÂÂ—Â‡Â”Â‡Â“Â—Â‹Â”Â‹ÂÂ‰
medical treatment but which does not require dialysis to resolv e, or a serum 
creatinine level >2.5 mg/dL at baseline (subject should not be enrolled) 
Restenosis Reoccurrence of narrowing or blockage or target lesion. 
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 62 of 6Íµ 
Rutherford 
Classification Clinical scale identifying three grades of claudication and thr ee grades of 
critical limb ischemia ranging from rest pain alone to minor an d major tissue 
loss. (ACC/AHA PAD Practice Guidelines â€“ Hirsch et al. 2005) 
Class  Clinical Description  
[ADDRESS_415810] pain  
5 Minor tissue loss  
6 Ulceration or gangrene  
Serious Adverse Device 
Event (SADE)  A serious adverse device effect (SADE) is defined as an adverse  device effect 
(ADE) that results in any of the  consequences characteristics o f a serious 
adverse event (SAE). (See ADE) 
Serious Adverse Event 
(SAE) A serious adverse event (SAE) is  defined an adverse event that:   
Âƒled to death
Âƒled to a serious deterioration in the health of the subject, th at either
resulted in:
Âƒa life-threatening illness or injury, or
Âƒresulted in a permanent impairme nt of a body structure or a bod y
function, or
Âƒrequired in-patient hospi[INVESTIGATOR_318251], or
Âƒresulted in medical or surgical intervention to prevent life-th reatening
illness or injury or permanent impairment to body structure or a body
function, or
Âƒled to fetal distress, fetal dea th or a congenital abnormality or birth
defect.
Note: Planned hospi[INVESTIGATOR_272] a pre-existing condition, or a procedure 
required by [CONTACT_336569], is 
not considered a serious adverse event.   
Standard Balloon 
Angioplasty  A standard balloon cat heter (non-drug-coated) used to perform p ercutaneous 
transluminal (balloon) angioplasty. Also referred to as Plain O ld Balloon 
Angioplasty (POBA)
Stroke A neurological deficit lasting m ore than 24 hours with a brain imaging 
study (if performed) showing infarction or hemorrhage. 
TOBA II Clinical Study Protocol â€“ Tack Endovascular System 
CA 0119 Rev B
CA 0119 Rev B CONFIDENTIAL Page 63 of 6Íµ 
Target Lesion Has a de novo or non-stented res tenotic target lesion indicated  f o r  P T A  
treatment with a standard or FDA-approved Lutonix drug-coated b alloon 
catheter that meets the fo llowing criteria below: 
a . 7 0 %  t o  9 9 %  s t e n o s i s  w i t h  a  t o t a l  l e s i o n  l e n g t h  o f  Î·20mm and
Î¶Í³Í·Í²ÂÂÂ‹ÂÂÂ‡ÂÂ‰Â–ÂŠÈ‹Â„Â› Â˜Â‹Â•Â—ÂƒÂÂ‡Â•Â–Â‹ÂÂƒÂ–Â‡ÈŒÂ‘Â”Ç¢
b . 1 0 0 %  o c c l u d e d  w i t h  a  t o t a l  l e s i o n  l e n g t h  Î¶100mm (by [CONTACT_336515])
Notes: A tandem lesion, defined as a lesion comprised of diseased 
and healthy segments, is eligible if the healthy segments are each not more than 30mm in length and all other criteria, 
including 3a and 3b above, are met A combination lesion, defined as a continuous lesion with 
both non-occluded and 100% occluded segments, is eligible 
if th e le s ion can be tr eat ed a s a sing le  le si on and all oth er  
criteria, including 3a and 3b above, are met 
c. A non-stented restenotic lesion must meet the following criter ia:
i. Meets criter ia 3a and 3b
ii. No part of the target lesion has been previously treated wit h
a drug-coated balloon
ii i. No pa rt of  the  targ et l es i on ha s h ad mor e than  2 previou s
PTA failures
iv. >[ADDRESS_415811] recent angioplasty treatment
Target Lesion 
Revascularization, 
Clinically-driven (CD-
TLR) Any re-intervention within the t arget lesion having angiographi c evidence of 
>50% diameter stenosis and the presence of symptoms associated with the 
target limb (defined as an incre ase in Rutherford Classificatio n and a decrease 
in ABI >0.15 from pre-dischar ge). 
Target Lesion 
Revascularization (TLR) A repeat revascularization proce dure (percutaneous or surgical)  of the 
original target lesion site.  
Target Vessel The superficial femoral artery ( SFA) and/or proximal popliteal artery (above 
Â–ÂŠÂ‡ÂÂÂ‡Â‡ÈŒÇ¡ÂÂ‘Â…ÂƒÂ–Â‡Â†Î·Í³Â…ÂÂ„Â‡ÂÂ‘Â™Â– ÂŠÂ‡Â…Â‘ÂÂÂ‘ÂÂˆÂ‡ÂÂ‘Â”ÂƒÂÂƒÂ”Â–Â‡Â”Â›È‹	ÈŒ  bifurcation 
to the distal segment of the pro ximal popliteal (P1) artery at the superior end 
of the patella. 
Target Vessel 
Revascularization, 
Clinically-driven non-
TLR (TVR-non TLR), Any re-intervention within the target vessel (excluding the tar get lesion) 
having angiographic evidence of >50% diameter stenosis and the presence of 
symptoms associated with the tar get limb (defined as an increas e in 
Rutherford Classification and a decrease in ABI >0.15 from pre- dischar ge). 
Target Vessel 
Revascularization, 
Clinically-driven (CD-
TVR) Any re-intervention within the target vessel having angiographi c evidence of 
>50% diameter stenosis and the presence of symptoms associated with the 
target limb (defined as an incre ase in Rutherford Classificatio n and a decrease 
in ABI >0.15 from pre-discharge). 
Target Vessel 
Revascularization (TVR) A repeat revascularization proce dure (percutaneous or surgical)  of the 
original target vessel.  
Unanticipated Adverse Device Event (UADE) An Unanticipated Adverse Device Effect (UADE) is any serious ad verse effect 
on health or safety or any life-threatening problem or death ca used by, or 
associated with, a device, if that effect, problem, or death wa s not previously 
identified in nature, severity , or degree of incidence in Â–ÂŠÂ‡Â‹ÂÂ˜Â‡Â•Â–Â‹Â‰ÂƒÂ–Â‹Â‘ÂÂƒÂÂ’ÂÂƒÂÇ¢
or any other unanticipated probl em associated with a device tha t relates to the 
ri
ghts, safety, or welfare of the subjects.  